Inchicore Bluebell Community Addiction Team – annual review 2014. by Grehan, Martin
1New report reveals the 
latest drug trends in Europe
In June 2015 the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) published the European drug report 2015: trends and developments, summarising the latest trends across the 
28 EU member states, and Norway and Turkey.1 The European drug 
report highlights changing dynamics in the heroin market, with an 
overall stagnation in the demand for heroin in Europe. The report warns, 
however, that an increase in production in most of the countries supplying 
Europe with heroin could result in more of the drug becoming available 
in European drug markets. Other changes in market dynamics, including 
processing of heroin inside Europe, the emergence of alternative trafficking 
routes and diversification of products from opioid-producing countries 
in Asia, need to be monitored carefully. As the age profile of heroin users 
increases, providing appropriate treatment and care to long-term users is a 
growing challenge for drug treatment and social services.
Cannabis continues to dominate reports on all drug law offences. Around 80% of all 
drug seizures are of cannabis, two thirds of which are herbal cannabis, demonstrating 
the importance of domestically produced herbal cannabis in the European drug market. 
Cannabis use is around five times more prevalent than use of other substances and 
the drug is now, for the first time, the most frequently cited reason for entering drug 
treatment in Europe. 
Responding to the report, Dimitris Avramopoulos, European Commissioner for 
Migration, Home Affairs and Citizenship, said: ‘The report shows that we are confronted 
with a rapidly changing, globalised drug market and, therefore, we need to be 
united, swift and determined in our response to the drugs threat.’ He continued: ‘I am 
particularly concerned that the Internet is increasingly becoming a new source of 
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supply, for both controlled and uncontrolled psychoactive 
substances. 101 new uncontrolled psychoactive substances 
were reported in 2014, challenging our existing control 
mechanisms. I look forward to the forthcoming EU 
legislation in this area, which is currently under negotiation.
This will further strengthen our responses and equip us 
with better instruments to deal with these substances more 
rapidly and more effectively.’
The situation described in the report is presented below 
under a series of headings. The European drug reports use 
the most recent data available to provide aggregate figures. 
While data on some indicators, such as treatment demand, 
are supplied annually, the year of the most recent prevalence 
data can vary.
Cannabis
 ■  The EMCDDA estimates that around 14.6 million young 
Europeans (11.7% of this age group, aged 15–34) used 
cannabis in the last year, and 8.8 million of these were 
aged 15–24 (15.2% of this age group). 
 ■  The use of cannabis in Europe has stablised or is declining, 
especially among younger age groups. The situation 
varies between countries. Of the 14 countries who have 
conducted new surveys since 2012, four reported lower 
estimates, two were stable and eight reported higher 
estimates than in previous comparable surveys.
 ■  Among the 3% of European adults (18–64 years) who 
used cannabis in the last month, about one quarter used 
cannabis on a daily, or almost daily, basis. 
European drug report (continued)
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EMCDDA select new director 
The European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) has selected Alexis Goosdeel 
(Belgium) as the agency’s new Director, starting on 
1 January 2016. Mr Goosdeel, a psychologist with a 
background in public health, has been head of the 
EMCDDA’s Reitox and international relations unit since 
2005. This work involves coordinating a network of 
30 national drug monitoring centres and preparing 
EU candidate and potential candidate countries for 
membership of the EMCDDA.
The EMCDDA is a special Lisbon-based EU agency. Its 
aim is to provide the EU and its member states with 
‘factual, objective, reliable and comparable information 
at European level concerning drug addiction and their 
consequences’. The EMCDDA was formally established in 
1993 and has been operational since 1995.
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 ■  The use of cannabis by school students aged 15–16 years 
varied considerably, from 5% in Norway to 42% in the 
Czech Republic.
 ■  Cannabis was the most frequently reported main problem 
drug among those entering treatment for the first time in 
2013. Between 2006 and 2013 the number of such clients 
increased from 45,000 to 61,000. For all clients entering 
treatment, cannabis was the second most frequently 
reported main problem drug, after heroin.
 ■  In 2013 there were 431,000 seizures of herbal cannabis, 
240,000 seizures of cannabis resin, 30,000 seizures 
of cannabis plants and 10,000 seizures of synthetic 
cannabinoids
 ■  While the number of seizures of herbal cannabis has 
exceeded those for cannabis resin every year since 2009, 
the quantity of resin seized in 2013 is still much higher 
(460 tonnes compared to 130 tonnes).
Opioids (mainly heroin)
 ■  The average prevalence of problem opioid use among 
European adults (aged 15–64) in 2012 is estimated 
at around 0.4%. This is the equivalent of 1.3 million 
problem opioid users in Europe.
 ■  In Europe 41% (175,000) of all clients who entered 
treatment in 2013 were users of opioids (mainly heroin).
 ■  The number entering specialist drug treatment for the 
first time for heroin use fell from a peak of 59,000 in 
2007 to 31,000 in 2013, accounting for 20% of all 
clients entering treatment for the first time.
 ■  In 11 European countries more than 10% of first-time 
opioid clients entering specialised treatment in 2013 
were misusing opioids other than heroin. In some 
countries, these drugs now represent the most common 
form of opioid use. 
 ■  Misused methadone was the most commonly reported 
of the drugs being misused by opioid clients entering 
specialised treatment in 2013 whose main problem drug 
was an opioid other than heroin, accounting for 60% of 
treatment demand by these clients.
 ■  Between 2006 and 2013 the median age of clients 
entering treatment for opioid use increased by five years. 
Many older opioid users are susceptible to a range of 
chronic health problems with implications for treatment 
and social support services.
 ■  Among opioid clients entering treatment in 2013, 33% 
reported injecting the drug.
 ■  Injecting continues to play a major role in the transmission 
of blood-borne infectious diseases such as the hepatitis C 
virus (HCV) and, in some countries, HIV/AIDS. There were 
1,458 newly reported HIV diagnoses attributed to injecting 
drug use in 2013, compared to 1,974 in 2012, the first 
time since 2010 a decrease has been recorded.
 ■  Of the 10 countries with national data available for 
2012–13, five reported a prevalence rate of more than 
50% for HCV antibodies among drug users. Six countries 
reported an increase, with only Norway recording a fall 
in HCV diagnoses. 
 ■  Heroin or other opioids were present in the majority of 
reported fatal overdoses. Overall, around 6,100 overdose 
deaths were reported in 2013, slightly up from the 
previous year and similar to the number reported in 2011. 
Between 2006 and 2013, the pattern has been one of 
decreasing numbers of overdose deaths among younger 
drug users and increasing numbers among older users. 
 ■  Heroin seizures have been declining in Europe since 
2010 and the number of seizures (32,000) and quantity 
seized (5.6 tonnes) in 2013 were among the lowest 
recorded in a decade.
Cocaine
 ■  Cocaine is the most commonly used illicit stimulant 
drug in Europe, although most users are found in a 
small number of countries. It is estimated that about 2.3 
million young European adults aged 15 to 34 (1.9% of 
this age group) used cocaine in the last year.
 ■  Only Spain and the United Kingdom reported last-year 
prevalence of cocaine use among young adults of more 
than 3%. Most countries with the highest prevalence 
rates for cocaine use among young adults over the past 
few years, have reported a peak in use in 2008 and a 
steady decline since then. 
 ■  Cocaine was the main problem drug for 55,000 clients 
entering specialised drug treatment in 2013, 15% of 
all those entering specialised treatment in that year. 
The number of clients entering treatment for the first 
time who cited cocaine as their primary drug has been 
decreasing in recent years, from a peak of 38,000 in 
2008 to 25,000 (16%) in 2012. Spain, Italy and the 
United Kingdom accounted for more than 70% of all 
those in treatment for cocaine use. 
 ■  The United Kingdom accounted for more than half of 
the 6,000 clients entering treatment in 2013 who cited 
crack cocaine as their primary drug. 
 ■  Across the 27 countries reporting data, at least 800 
deaths related to cocaine use were recorded in 2013.
 ■  In 2013, around 78,000 seizures of cocaine were 
reported in the European Union, amounting to 63 
tonnes. There was a significant increase in both seizures 
and volume between 2008 and 2010, and the situation 
has been relatively stable since then. 
Other stimulants and new psychoactive substances
 ■  While lifetime use of new psychoactive substances (NPS) 
remains at a low level among young people, the number 
of new NPS reported continues to grow. These data are 
based on notifications by member states to the EU Early 
Warning System (EWS). During 2014 the EWS identified 
101 NPS for the first time, an increase of 25% on 2012. 
 ■  Of the NPS detected for the first time, 31 were 
synthetic cathinones and 30 were synthetic 
cannabinoids. Other substance groups monitored 
are substituted phenethylamines tryptamines and 
piperazines. Thirteen newly reported compounds do 
not conform to the readily recognised chemical groups 
(including plants and medicines).
 ■  The EWS has identified more than 70 new cathinone 
derivatives. In 2013, over 10,000 seizures of synthetic 
cathinones were reported to the EWS, the best known 
being mephedrone, controlled in Europe since 2010 
but becoming increasingly important in the stimulants 
market in some countries. Cathinones are used in 
similar ways to, and often interchangeably with, other 
stimulants such as amphetamine and MDMA.
 ■  Around 1.3 million Europeans used amphetamines 
during the last year. 
European drug report (continued)
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Ireland’s national suicide strategy  
2015–2020, and the evidence base 
On 18 June 2015 the Taoiseach, Enda Kenny TD, launched 
Ireland’s national suicide strategy Connecting for life.1 The 
strategy envisions an Ireland where fewer lives are lost 
through suicide, and where communities and individuals are 
empowered to improve their mental health and wellbeing. 
This vision will be achieved through seven goals:
1. Better understanding of suicidal behaviour
2.  Supporting communities to prevent and respond to 
suicidal behaviour
3.  Targeted approaches for those vulnerable to suicide 
including alcohol and drug users
4.  Improved access, consistency and integration of services
5. Safe and high-quality services
6. Reduced access to means
7. Better data and research
The outcomes expected by 2020 are a reduced suicide rate 
in the population and among specified priority population 
groups, and a reduced rate of presentations of self-harm in 
the whole population and among specified priority groups. 
The strategy will be implemented by a National Cross-
Sectoral Steering and Implementation Group.
The most common disorders associated with suicidal 
behaviour are depression and alcohol and other substance 
use disorders which are found in 25–50% of all suicides. 
People with alcohol and drug problems are one of the 
specified priority population groups. The HSE will continue 
to roll out programmes aimed at early intervention and 
prevention of alcohol and drug misuse. Their campaigns will 
build a link between alcohol and/or drug misuse and suicidal 
behaviour in all communications. 
Evidence for effectiveness of suicide  
prevention interventions
On the same day as Connecting for life was launched, the 
Health Research Board (HRB) published its evidence review 
of the effectiveness of suicide prevention interventions.2 The 
HRB was commissioned by the National Office of Suicide 
Prevention (NOSP) to examine the international evidence 
base for suicide prevention in order to establish which 
interventions were successful in reducing suicidal behaviour 
including suicide ideation, self-harm, suicide attempts or 
death by suicide. 
The HRB used 34 published reviews, some of which 
covered more than one intervention. The HRB review 
assessed five interventions (means restriction, media 
guidelines, gatekeeper training, screening and psychosocial 
interventions) and four settings (telemental health, web-
based interventions, emergency departments (EDs), schools 
and youth strategies).
Overall, the review found the body of evidence on suicide 
prevention interventions to be limited but some important 
interventions reduced suicidal behaviours. These are 
restricting access to means of suicide, cognitive behavioural 
therapy* and dialectic behavioural therapy.** Suicide 
prevention interventions in ED settings (for example, 
reviews of treatment and expectations) also show promise. 
Telemental health and web-based interventions have only 
emerged recently and there is not enough evidence to 
comment on their success. Table 1 summarises the findings. 
The authors recommend that all these interventions should 
continue to be studied so that stronger evidence-based 
conclusions can be reached. Published evidence in relation 
to suicide prevention interventions is limited. This does 
not mean that interventions are ineffective, but rather that 
there is little evidence published in peer-review journals. 
In addition, the societal context is important and there is a 
need for further high-quality research that takes account of 
the Irish context. 
The HRB welcomes the strategic approach adopted in 
Connecting for life and in particular its focus on monitoring 
and evaluation.
(Jean Long)
*   Cognitive behavioural therapy (CBT) is an action-oriented 
form of psychosocial therapy that focuses on changing an 
individual’s thoughts (cognitive patterns) in order to change 
his or her behaviour and emotional state.
**   Dialectic behavioural therapy (DBT) is a type of cognitive 
behavioural therapy. Its main goal is to teach a person 
skills to cope with stress, regulate emotions and improve 
relationships with others. 
1.   Department of Health, Health Service Executive and 
National Office for Suicide Prevention (2015) Connecting for 
life: Ireland’s national strategy to reduce suicide 2015-2020. 
Dublin: Department of Health http://www.drugsandalcohol.
ie/24167/
2.   Dillon L, Guiney C, Farragher L, McCarthy A and Long J (2015) 
Suicide prevention: an evidence review 2015. Dublin: Health 
Research Board. http://www.drugsandalcohol.ie/24168/
 ■  Ecstasy contains the synthetic substance MDMA. It is 
estimated that 1.8 million young European adults (aged 
15–34), 1.4% of this age group, used ecstasy in the last 
year. Decreasing prevalence of ecstasy use has been 
reported in all countries that have sufficient data to allow 
exploration of trends. 
Accompanying the European drug report are Perspectives on 
drugs (PODs), online interactive articles providing insight 
into specific issues in the drugs field. 
The four themes in focus this year are misuse of 
benzodiazepines among high-risk drug users, psychosocial 
interventions, drug consumption rooms, and heroin 
trafficking routes.
(Brian Galvin)
1.  European Monitoring Centre for Drugs and Drug Addiction 
(2015) European drug report 2015: trends and developments. 
Luxembourg: Office for Official Publications of the European 
Communities. http://www.emcdda.europa.eu/
European drug report (continued)
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National suicide strategy (continued)
Table 1: Summary of main suicide prevention interventions and settings, and evidence for their impact  
Intervention 
and/or Setting
 
Description
 
Evidence
 
Comment
Means 
restriction
Restricts access to means of 
completing suicide.
4 reviews 
examined.
Good evidence that 
interventions work.
The evidence shows that means 
restriction (in particular, barriers) can 
reduce the occurrence of suicide. Other 
international reviews report that controls 
on the use of chemicals and drugs have 
been found to successfully reduce  
suicide outcomes.
Media guidelines Based on the premise that media 
reporting of suicides can contribute to 
the phenomenon of imitative suicides, 
some countries have introduced 
guidelines for reporting.
1 review examined.
Some limited 
evidence that 
intervention works.
This evidence is based on Austria’s 
experience where the media were 
involved in designing national guidelines 
and subsequently complied with them.
Gatekeeper 
training
Teaches people how to identify people 
at risk and refer them to treatment.
1 review examined.
Some limited 
evidence that 
intervention works 
and works best 
if the GP is the 
gatekeeper.
This evidence is based on the impact 
of multi-faceted strategies to prevent 
suicide that had gatekeeper training as 
one of a number of interventions in place. 
Therefore, it is difficult to ascertain what 
specific role gatekeeper training played in 
delivering suicidal behaviour outcomes.
Screening Uses psychometrically validated 
screening instrument to identify people 
at risk of suicide.
Three reviews 
examined.
Evidence mixed  
but weak.
The evidence base for the impact of 
screening on suicidal behaviours is mixed 
but relatively weak.
Psychosocial 
interventions
Psychotherapeutic interventions cover  
a wide range of interventions 
including cognitive behavioural 
therapy (CBT), dialectic behavioural 
therapy (DBT), problem-solving 
therapy and family therapy. 
Enhanced care/outreach/follow-up 
include interventions to help people 
at risk of suicide to access/maintain 
contact with services by means such 
as follow-up postcards, 24-hour 
emergency access to psychiatric 
services and home visits.
13 reviews 
examined.
Revealed a mixed 
picture across 
the various 
interventions.
Overall, CBT and DBT are the 
psychotherapies for which there is the 
best evidence of impact on reducing 
suicidal behaviour.
Problem-solving therapy and family 
therapy showed evidence of promise as 
effective interventions, but evidence was 
not conclusive. 
Evidence across the different types of 
enhanced care interventions  
is inconclusive. 
Telemental 
health 
Uses communications networks to 
provide mental health care services 
and education from one geographical 
location to another. 
Two reviews 
available. Limited 
evidence.
Given the current evidence base it 
is difficult to draw firm conclusions 
regarding the impact of telemental 
health on suicidal outcomes.
Web-based 
prevention 
This approach is based on the premise 
that people vulnerable to suicide 
frequently access web-based resources 
as a source of support. Web-based 
strategies for suicide prevention are 
only emerging.
One review.
Preliminary 
evidence that  
this approach 
could work.
Preliminary evidence in the one review 
available suggests that web-based 
intervention strategies may be beneficial 
in helping to reduce suicidal behaviours. 
Emergency 
Department (ED) 
interventions
EDs have been identified as important 
settings in which to evaluate and 
alleviate suicide emergencies, instigate 
follow-up care and reduce suicide 
symptoms. 
One review.
Limited but 
promising evidence 
that interventions 
in this setting work.
Care that was initiated in EDs and/
or continued post-ED discharge was a 
promising method that may be beneficial 
in reducing suicide.
School-based 
interventions
Interventions in this setting are 
based on the premise that providing 
programmes in schools, such 
as knowledge and awareness, 
gatekeeper training, curriculum-based 
programmes, screening, skills training 
and/or peer leadership, can influence 
whether completed suicide occurs.
Eight reviews.
No evidence that 
these interventions 
reduce suicidal 
behaviours.
The effectiveness or ineffectiveness of 
school-based prevention programmes in 
reducing suicidal behaviours has yet to 
be determined. 
Source: Dillon et al. (2015) 
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IMO targets addiction and dependency 
On 11 June 2015 the Irish Medical Organisation (IMO) 
launched a policy paper on addiction and dependency.1 
Speaking at the launch, IMO President, Dr Ray Walley, 
said: ‘Addiction and dependency are some of the most 
challenging public health policy issues of recent times and 
IMO doctors are advocating for sensible and workable 
measures that should be examined by legislators and 
policy-makers to loosen the grip that substance abuse and 
addiction has placed on large tracts of our society.’
 
Alcohol
Key actions called for by the IMO include:
 ■  the implementation of the National Alcohol Strategy 
without delay and immediate action to ban sponsorship 
and promotion of sports by the alcohol industry, 
 ■  introduction of minimum unit pricing for alcohol 
products, and
 ■  creation of a strategy for the development of  
treatment and rehabilitation services for alcohol and 
drug dependency.
Gambling
The IMO believes that regulatory controls to limit the 
exposure of young people to gambling should be instigated 
immediately, including controls that limit the intensity or 
frequency of gambling service advertisements. Given the 
prevalence of gambling in Ireland, and the increased access 
that most young people and adults have to gambling 
through smartphones and other portable internet-enabled 
devices, effective educational programmes are needed to 
raise awareness of problem gambling in the Social, Personal, 
and Health Education (SPHE) curriculum. Funding is also 
needed for research into the extent of problem gambling 
and its effects on individuals and their families in Ireland.
Treatment and rehabilitation services
The IMO urges the government to create a strategy for the 
development of treatment and rehabilitation services for 
alcohol and drug dependency to include: 
 ■  establishment of acute alcohol and illicit drugs 
detoxification centres for those who wish to choose 
detoxification as part of their recovery;
 ■  development of appropriate acute treatment facilities for 
those with alcohol and benzodiazepine dependency;
 ■  full implementation of the Farrell Report (2010)2 to allow 
for the expansion of numbers of patients on the Opioid 
Treatment Protocol and thus increase access to treatment 
for heroin dependence throughout the country;
 ■  pursuit of research that will assess the potential benefits 
and risks of using supervised injection sites as a means of 
reducing drug-related harm and bringing patients into 
contact with drug treatment services;
 ■  development of specialist services in dual-diagnosis, 
comorbid substance dependency and mental health 
illness, with appropriate pathways of referral in and out 
of services and standardised protocols for care;
 ■  appropriate training of all physicians in treatment of 
addiction and dual-diagnosis, both as part of the core 
curriculum and continuing professional development; and
 ■  provision of state funding for the treatment of  
gambling addiction. 
Reducing the social cost of addiction
 ■  Introduce spent convictions legislation that will allow 
minor crimes to be removed from an individual’s criminal 
record, to better enable those convicted of minor 
possession offences to re-enter the workforce.
 ■  Develop an effective substance abuse and dependence 
intervention programme, incorporating a referral 
procedure, for people who have come to the attention of 
various State authorities, such as An Garda Síochána or 
officers of the Department of Social Protection.
 ■  Establish a cross-departmental integrated approach to 
treatment and rehabilitation to ensure the education, 
housing, and social protection needs of patients and 
their families are met.
 ■  Provide financial support to local and regional drugs task 
forces and social services to address child- and family-
related drug problems.
Funding prevention and treatment
 ■  Ensure that contributions from the alcohol and  
gambling industries fund the treatment and 
rehabilitation of those who have developed clinical 
dependencies on their products.
 ■  Route proceeds acquired by the Criminal Assets  
Bureau relating to drug crime to investment in drug 
treatment programs.
Reducing supply 
Finally, the IMO urges the government to restore all 
resources to state agencies charged with seizing and 
intercepting drugs shipments, thereby affecting their 
availability and price in a manner that will reduce 
consumption. Stiff penalties are also called for to deter  
the importation and sale of illegal drugs into Ireland.  
The IMO recommends that mandatory life sentences  
should be imposed on those found guilty of major drug 
trafficking crimes. 
(Brigid Pike)
1.  Irish Medical Organisation (2015) IMO position paper on 
addiction and dependency. Dublin: Irish Medical Organisation. 
http://www.drugsandalcohol.ie/24092/ 
2.  Farrell M and Barry J (2010) The introduction of the opioid 
treatment protocol. Dublin: Health Service Executive.  
http://www.drugsandalcohol.ie/14458/ 
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CityWide starts debate ahead of  
UNGASS 2016
Everyone knows that in a few months’ time, April 2016, the 
UN General Assembly will be holding a two-day debate on 
the UN’s drug prohibition policy. It is the first time that all 
190-odd UN member states have debated the drugs issue 
since 1998, when they voted for a plan to make the world 
drug-free by 2008. Reviewing this plan in 2009, the member 
states agreed the drugs issue remained a ‘serious problem’, 
and voted in a new political declaration and plan of action to 
continue tackling the problem.1 
The purpose of the 2016 UNGASS debate is to review 
progress in implementing the 2009 political declaration 
and action plan, and to assess the achievements and 
challenges in countering the world drug problem.2 That 
small clause, to assess the achievements and challenges, is 
causing a huge amount of discussion and debate among 
and within governments and civil society around the world.3
Ireland is no exception. On 4 September 2015, the CityWide 
Drugs Crisis Campaign hosted a public event in Dublin, 
which included a screening of the film Breaking the taboo,4 
followed by a panel discussion and audience Q&A session 
on the future of the ‘war on drugs’. The panel comprised Sir 
Richard Branson, founder of the Virgin Group and member 
of the Global Commission on Drug Policy, Aodhán Ó 
Ríordáin, Minister of State with responsibility for the National 
Drugs Strategy, Bernie McDonnell, Director of Services, 
Community Awareness of Drugs, and Fr Peter McVerry, social 
justice campaigner. Keelin Shanley, broadcaster and RTÉ 
journalist, was moderator of the discussion. 
Made in 2011, Breaking the taboo is a film documentary 
about the last 40 years of the ‘war on drugs’, focusing on 
Columbia, Brazil, Mexico, the United States and Afghanistan. 
In Mexico and Columbia alone, over 100,000 people have 
been killed in recent decades owing to the operations of 
drug cartels and organised criminal gangs involved in the 
illicit drugs trade. The film ends by examining the case 
put forward by the Global Commission on Drug Policy, 
in a report published in 2011,5 for drug liberalisation as 
the best way of dealing with the drug problem: it looks at 
decriminalisation of drug use, provision of safe injecting 
facilities, and regulation of the drug market. 
In the panel discussion that followed, the Minister reiterated 
his commitment to facilitating the piloting of a safe injecting 
facility in Dublin before the end of 2015, and indicated 
his support for the decriminalisation of cannabis use. He 
acknowledged that decriminalisation was unlikely to be 
achieved during the lifetime of the present government. 
The arguments for and against these two options took up 
much of the panel discussion and the audience Q&A session. 
Thus, it is apparent that Ireland has broken the taboo on 
talking about the challenges on the demand side of the drug 
problem. But by the same token, it is apparent Ireland has 
not broken the taboo on talking about the challenges on  
the supply side. 
And yet it was concerns about the supply side that led 
South American countries Columbia, Guatemala and 
Mexico to call for UNGASS 2016.6 Writing in 2012 from 
their own devastating experiences, these countries warned 
that ‘transnational organized crime and, in particular, 
the violence that it spreads in the course of its criminal 
activities, represent a serious problem that compromises the 
development, security and democratic life of all nations,...’. 
They called for member states to intensify their efforts with 
regard to the prevention and punishment of crime, the 
provision of social programmes in education, health, leisure 
and employment, and the prevention and treatment of 
addictions so as to preserve the social fabric. On the supply 
side they called for a paradigm shift:
That the United Nations should exercise appropriate 
leadership in this effort and conduct a process of  
in-depth discussion in order to analyse all the 
available options, including regulatory or market 
measures, with a view to establishing a new 
paradigm for preventing the flow of resources to 
organized crime organizations; 
At the CityWide event in Dublin in early September, Minister 
Ó Ríordáin was careful to stress that when he talked about 
decriminalisation, he was not talking about legalisation: 
decriminalising the possession of small amounts of cannabis 
does not mean legalising the supply of cannabis. Although 
the concept of regulation was examined in the course of the 
film Breaking the taboo, the word was not mentioned by the 
Minister or by any other contributors at the CityWide event.
‘Legalisation’ implies the removal of all legal restrictions 
on the drug market, which in turn suggests ‘open slather’. 
‘Regulation’ on the other hand, which was discussed in the 
film and which was explicitly mentioned by the sponsors of 
the UNGASS resolution, implies control – of the production, 
distribution, sale and consumption of drugs – in other 
words, control of both supply and demand.
In recent years a growing number of countries have begun 
experimenting with various regulatory approaches to 
the illicit drug market – coffee shops in the Netherlands, 
cannabis clubs in Spain, a strict government-controlled 
cannabis market in Uruguay, commercial recreational 
marijuana operations in various states in the USA, and the 
licensing for sale of psychoactive substances clinically proven 
to be ‘low risk’ in New Zealand. While regulating the illicit 
drug market is still largely uncharted territory, with uncertain 
outcomes, policy analysts argue there are compelling 
reasons to press ahead with such experiments,7 and a 
recent review of risks commonly associated with cannabis 
regulation finds that the evidence for risks is ‘weak’  
(see Table 1).8 
CityWide Conference
As part of the celebrations of its 20th anniversary, 
CityWide is holding a one-day conference on 12 
November on the theme of Drug Policy Reform.  
See page 32 below for further details.
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Table 1: Common claims regarding cannabis regulation and the supporting evidence
Claim Strength of Supporting 
Evidence
Bottom Line
Legalization / regulation 
increases the availability of 
cannabis
Weak Evidence suggests that the supply of illegal cannabis has 
increased under a prohibition model, and that availability 
has remained high among youth. Evidence does not 
suggest that cannabis availability among youth has 
increased under regulatory systems.
‘[I]f marijuana was legalised, 
the increase in users would be 
both large and rapid...’
Weak Evidence suggests that the policy environment (specifically 
legal status and enforcement policy) has at most a marginal 
impact on the prevalence of drug use, thereby suggesting 
that regulating cannabis markets will not inevitably cause 
higher levels of cannabis use.
Regulation will not reduce 
drug crime
Weak Given that the prohibition of cannabis has not been shown 
to reduce illegal supply, it is likely that cannabis regulation is 
more effective at minimizing criminal markets for cannabis, 
despite the fact that criminal markets will continue to 
represent a proportion of the total market.
‘We are going to have a lot 
more people stoned on the 
highway and there will be 
consequences’
Weak While experimental studies suggest that cannabis 
intoxication reduces motor skills and likely increases the risk 
of motor-vehicle collisions, there is not sufficient data to 
suggest that cannabis regulation would increase impaired 
driving, and thereby traffic fatalities.
Regulation promotes drug 
tourism
Weak There is a great deal of uncertainty regarding cannabis 
regulation and so-called ‘drug tourism’ and it is likely that 
such activity will vary across different jurisdictions based on 
the use of different regulatory controls.
Regulation leads to a ‘Big 
Marijuana’ scenario.
Weak Available evidence regarding ‘Big Marijuana’ is currently 
lacking, though regulatory controls can be introduced 
within regulatory systems to reduce the potential of profit 
maximisation by cannabis retailers.
Source: Werb et al. 2015: 23
While there may be good reasons to resist the arguments 
and the analysis supporting experiments in regulation, a 
preliminary paragraph in the 2009 UN Political Declaration 
with regard to the world drug problem nevertheless 
indicates that governments and civil society organisations 
should at least ensure a balanced consideration of the 
achievements and the challenges on both the supply and 
the demand side of the illicit drug problem:
… the world drug problem remains a common and 
shared responsibility that requires effective and 
increased international cooperation and demands 
an integrated, multidisciplinary, mutually reinforcing 
and balanced approach to supply and demand 
reduction strategies.1
(Brigid Pike)
1.  UN Office of Drugs and Crime (2009) Political declaration 
and plan of action on international cooperation towards an 
integrated and balanced strategy to counter the world drug 
problem. https://www.unodc.org/documents/ungass2016/
V0984963-English.pdf 
2.   Resolution adopted by the General Assembly [on the report of 
the Third Committee (A/67/459): International cooperation 
against the world drug problem. A/RES/67/193 
3.  https://www.unodc.org/ungass2016/ for background and 
up-to-date information on preparations for UNGASS 2016.
4.  Breaking the taboo film viewed on 8 September 2015 at 
https://www.youtube.com/watch?v=h7Cyhq8HRVE 
5.  Global Commission on Drug Policy (2011) Report of the 
Global Commission on Drug Policy. Rio de Janeiro: Global 
Commission on Drug Policy. http://www.drugsandalcohol.
ie/15228/ 
6.  Letter dated 2 October 2012 from the Permanent 
Representatives of Colombia, Guatemala and Mexico to the 
United Nations addressed to the Secretary-General. A/67/493
7.  Caulkins JP, Hawken A, Kilmer B and Kleiman MAR (2012) 
Marijuana legalization: what everyone needs to know. New 
York: Oxford University Press. 
8.  Werb D, Watson TM and Maghsoudi N (2015) State  
of the evidence: cannabis use and regulation. Toronto: 
International Centre for Science in Drug Policy.  
http://www.drugsandalcohol.ie/24325/ 
CityWide starts debate (continued)
9drugnet 
IRELAND
Towards UNGASS 2016 
Since Issue 48, Drugnet Ireland has carried ‘Towards UNGASS 
2016’ as a regular column. It reports on policy initiatives, 
research and debates launched by the UN, member states and 
civil society organisations in the lead-up to the UN General 
Assembly Special Session (UNGASS) on the world drug problem, 
due to be held in New York on 19–21 April 2016. 
www.ungass2016.org
Released early in 2015, the E-Book of Authorities 
catalogues agreed UN statements and language on 
a selection of topics, to show the extent of existing 
international support for evidence-based drug policies. 
The objective of the E-Book of Authorities is to help 
inform international drug policy discussions, debates and 
negotiations. The topics covered include:
 ■ Human rights
 ■ Harm reduction
 ■ Death penalty
 ■  Access to controlled substances for medical and  
scientific purposes
 ■  Flexibilities of the UN drug conventions regarding 
alternatives to punishment for certain drug offences
 ■ Cultivation and alternative development
 ■ Civil society engagement.  
This e-tool is maintained by a coalition of partners including 
the International Drug Policy Consortium, Harm Reduction 
International and the Transnational Institute, and is funded 
by the United Nations Office on Drugs and Crime and Open 
Society Foundations. http://bookofauthorities.info/about/
Between 9 and 21 March 2015 the Commission on 
Narcotic Drugs (CND), which supervises the application 
of the international drug control treaties, held its 58th 
Session in Vienna, including a special segment on the 
preparation for UNGASS 2016. In the run-up to the Session, 
the International Narcotics Control Board and the UN 
Development Program published reports intended to inform 
the deliberations of the 53 member states that currently 
comprise the CND. These two reports are described below.
http://www.unodc.org/unodc/en/commissions/CND/
session/58_Session_2015/CND-58-Session_Index.html 
In early March 2015 the International Narcotics Control 
Board (INCB) published its Annual Report, which provides a 
comprehensive survey of the drug control situation in various 
parts of the world. In his introduction, the chairperson of the 
INCB, Lochan Naidoo, states that as the goal of the United 
Nations legal framework on drugs is ‘the safeguarding of 
the health and welfare of humankind … one of the most 
fundamental principles underpinning the international drug 
control framework, enshrined in both the 1961 Convention 
and in the Convention on Psychotropic Substances of 1971, 
is the limitation of use of narcotic drugs and psychotropic 
substances to medical and scientific purposes. This legal 
obligation is absolute and leaves no room for interpretation.’
With an eye on UNGASS 2016, the INCB devotes Chapter 
1 of its annual report to reiterating the need to adopt ‘a 
comprehensive, integrated and balanced approach to 
implementing the provisions of the international drug control 
treaties in order to respond to the world drug problem 
together’. The elements of such an approach comprise:
 ■  Availability of internationally-controlled substances for medical 
and scientific purposes: Despite the progress made in some 
regions, the report acknowledges that approximately three 
quarters of the world’s population live in countries with 
inadequate or non-existent access to medicines containing 
narcotic drugs and psychotropic substances, which leads 
to unnecessary pain and suffering.
 ■  Demand reduction: The report cites articles in the drug 
treaties that stipulate that member states ‘shall take 
all practicable measures for the prevention of abuse of 
narcotic drugs and psychotropic substances and for 
the early identification, treatment, education, aftercare, 
rehabilitation and social reintegration of the persons 
involved’. The INCB recommends that member states 
put greater emphasis on, and provide political support 
and appropriate resources to, these efforts, to ensure a 
proper balance between demand and supply reduction.
 ■  Supply reduction: Without demand reduction, the report 
asserts that supply reduction cannot be effective in the 
long run. As well as responding effectively to emerging 
challenges such as new psychoactive substances and 
changing drug supply routes, the report calls for specific 
efforts to focus on depriving the illicit drug economy of its 
commercial attractiveness and for dismantling its socio-
economic basis, for example disrupting illicit financial 
flows connected to drug trafficking, undermining the links 
between illicit drugs and other forms of criminal activity, 
and preventing people from being recruited by drug 
traffickers by addressing the socio-economic conditions that 
contribute to their becoming involved in the first place.
 ■  Socio-economic aspects: Poverty, food insecurity, 
economic inequality, social exclusion, deprivation 
owing to migration and displacement, a shortage of 
comprehensive educational and recreational facilities 
and employment prospects, poor parental engagement 
and guidance during childhood, and exposure to 
violence and abuse are all listed as factors contributing 
to both the supply and demand sides and affecting the 
interaction between the two sides. 
 ■  Socio-cultural aspects: Influencing or changing people’s 
perceptions in relation to illicit drugs is seen mainly as 
a prevention matter. But it is also affected to a certain 
extent by the overall structure of drug control policy 
and the image it projects: imbalanced approaches to 
different aspects can diminish public support. The main 
element of sustainable success is not reactive approaches 
alone, according to the report, but rather the fostering of 
a ‘preventive culture’, one that is resistant to the appeal 
of popular culture that promotes drug use.  
http://www.incb.org/incb/en/publications/annual-
reports/annual-report-2014.html 
In early March 2015 the UN Development Program published 
Perspectives on the development dimensions of drug control 
policy. While drug control policies have been justified by 
’the real and potential harms associated with illicit drug 
production, trafficking, and use’, the report points out that 
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various UN organisations have observed that these policies 
have had ‘harmful collateral consequences: creating a criminal 
black market; fuelling corruption, violence, and instability; 
threatening public health and safety; generating large-scale 
human rights abuses, including abusive and inhumane 
punishments; and discrimination and marginalization of people 
who use drugs, indigenous peoples, women, and youth’. The 
report goes on to note that the UN Office on Drugs and Crime 
(UNODC) has stated that ‘the UN drug conventions do not 
require penalization of drug use or drug possession for personal 
use’ and that the UNODC Executive Director, Yuri Fedotov, has 
encouraged UN member states to use UNGASS 2016 as an 
opportunity to ‘discuss ways to rebalance international drug 
control policy responses to focus on health and respect for 
human rights, and address stigma and discrimination that limits 
access to services by people who use drugs’. http://www.
unodc.org/documents/ungass2016/Contributions/UN/
UNDP/UNDP_paper_for_CND_March_2015.pdf 
UNGASS 2016 (continued)
Judging prohibition
Given the growing international debate about the merits 
of the so-called war on drugs, ‘So prohibition can work?’ 
is the provocative title of a recent article which reports on 
a study that considered the impact of the Criminal Justice 
(Psychoactive Substances) Act introduced in Ireland 2010 in 
response to the ‘headshop’ phenomenon.1 This legislation 
led to the closure of 90% of the headshops then in existence 
throughout Ireland.2 The study examined the use of new 
psychoactive substances (NPS) by adolescents attending 
addiction treatment both before and after the introduction 
of the legislation. Included in the study were all adolescents 
entering assessment at one outpatient service, comparing 
the six months immediately prior to the legislation in May 
2010 with the same six-month period the following year. 
There were 94 treatment episodes included, and the 
patients had a mean age of 16.8 years. Problematic use 
of any NPS fell from 34% (14) of patients in the pre-
legislation period to no patients after the introduction of 
the legislation. There was also a significant decline in recent 
use of any NPS (82% vs 28%). Recent use of cocaine and 
amphetamines also declined, but problematic use of these 
drugs was unchanged. The authors concluded that the 
use of NPS among adolescents attending drug and alcohol 
treatment was substantially reduced 6–12 months after the 
legislation was introduced and after most head shops had 
closed. Adolescents attending after the ban also showed 
‘significantly lower rates of both recent use and problematic 
use of any NPS’ (p. 3). 
In discussing their findings, the authors made the following 
observations: ‘…our study cannot explain why these 
adolescents reduced their NPS use. It seems unlikely that 
concerns regarding criminal sanctions acted as an important 
deterrent. They demonstrated ongoing use of a broad 
range of similarly illegal drugs after the legislative ban’ (p. 
3). Highlighting the main impact of the ban, the closure of 
the headshop outlets, the authors make the point: ‘Looking 
beyond NPS, we know that availability is a key factor 
influencing use of other substances, such as cannabis and 
alcohol. …In the months following legislation 93% of the 
headshops closed thereby curtailing easy access to these 
drugs’ (p. 3). 
In this respect, the study supports the contention of the 
United Nations Office on Drugs and Crime (UNODC) 
and other advocates of prohibition that rates of drug use 
and related harms would be higher but for prohibition. 
However, many uncertainties remain about the long-term 
impact of the legislative ban. A study by Kelleher and 
colleagues on the legislative changes predicted that ‘the 
reduction in the supply of NPS will lead to displacement of 
drug consumption choice’, bringing with it ‘a new set of 
risks to customers’ (p. 141).3 In recent years, online illicit 
drug sales have increased and an active street market for 
the sale of prescription drugs, including benzodiazepines, 
has developed. Kelleher and colleagues also revealed a  
sub-group of recreational users of NPS who were not 
coming into contact with healthcare professionals and 
it is unclear how the legislation impacted on their drug 
consumption behaviours. 
A number of commentators criticised Ireland’s legislative 
approach to the headshop issue. Reuter, referring to a 
regulatory impact analysis conducted by the Department 
of Justice and Equality prior to the introduction of the Act,4 
stated that the approach adopted was ‘of limited conceptual 
sophistication’ and ultimately naïve:5 ‘The assessment makes 
no mention of any potential adverse effects of prohibition. 
It identifies the dangers of not regulating and the potential 
gross gains of the regulatory options. The only negative 
aspects of regulation that are given any attention are the 
costs of operating the regulation’ (p. 7).
In a similar vein, Ryall and Butler argued that, from a 
harm reduction perspective, the policy response was as an 
example of ‘moral panic in that media portrayals greatly 
exaggerated the ill effects of head shop products, in the 
process stoking public anger rather than encouraging 
rational debate’ (p. 303).6 Although the authors 
acknowledged ‘a degree of sophistication’ on the part of 
the various stakeholders at the time, including headshop 
owners, users, law enforcement personnel, policy advisers 
and the minister responsible for the National Drugs Strategy, 
ultimately they concluded that ‘the great Irish head shop 
controversy ended in a clear victory for traditional “war on 
drugs” values’ (p. 310).
Current plans in the UK to introduce legislation modelled 
on the Irish approach look set to revive the headshop 
controversy. Ultimately, it may also lead to further critical 
examination of the consequences of prohibition in general.7 
(Johnny Connolly)
1.  Smyth BP, James P, Cullen W and Darker CD (2015) 
“So prohibition can work?” Changes in use of novel 
psychoactive substances among adolescents attending a 
drug and alcohol treatment service following a legislative 
ban International Journal of Drug Policy, Early online.  
http://www.drugsandalcohol.ie/24190/
2. Connolly J (2012) Impact of legislation to control head   
shops Drugnet Ireland(40): 29.  
http://www.drugsandalcohol.ie/16890/ 
3. Kelleher C, Christie R, Lalor K et al. (2011) An overview of 
new psychoactive substances and the outlets supplying them 
Dublin: National Advisory Committee on Drugs.  
http://www.drugsandalcohol.ie/15390  
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The Misuse of Drugs (Amendment) Act 2015 had to be 
introduced as emergency legislation after a court struck 
down a series of regulations introduced over the past two 
decades banning certain drugs.1 In what the Court of Appeal 
said was a ‘constitutional issue of far-reaching importance’, 
the three-judge court unanimously said a regulation making 
the possession of methylethcathinone illegal was invalid.2 
The substance is also known as 4-Mec or Snow Blow. 
The judgement raises a number of questions about the 
rationale behind the Misuse of Drugs Act 1977, the principal 
legislation that underlines drug prohibition in Ireland. 
In particular, it raises questions about the way in which 
concepts such as drug harm and drug misuse are defined 
and incorporated into the criminal law. This article presents 
an edited version of the judgement.
The State successfully defended the original case in a 
High Court hearing in March 2014. The matter was then 
appealed to the Court of Appeal. At issue in the case was 
the constitutionality of s. 2(2) of the Misuse of Drugs Act 
1977. This provision states: ‘The Government may by order 
declare any substance, product or preparation (not being a 
substance, product or preparation specified in the Schedule 
to this Act) to be a controlled drug for the purposes of this 
Act and so long as an order under this subsection is in force, 
this Act shall have effect as regards any substance, product 
or preparation specified in the order as if the substance, 
product or preparation were specified in the said Schedule.’ 
The court held that this section, under which regulations 
banning numerous substances have been introduced over 
the past two decades, was unconstitutional because it 
purported to vest in the Government law-making powers 
which are in the exclusive authority of the Oireachtas. 
In doing so, the court decided that this section of the 
Act failed the ‘principles and policies’ test.3 This test is 
designed to prevent a Minister or administrative agency 
from deciding matters that are properly the concern of the 
Oireachtas (Parliament). Under article 15.2.1 of the Irish 
Constitution, the sole power of making laws in the state is 
vested in the Oireachtas.
The original case concerned the prosecution of a man for 
possession of methylethcathinone, which was among a 
number of substances put on the controlled drugs list in 
2010. Stanislav Bederev, who denied criminal charges of 
having the substance for supply in 2012, brought a High 
Court challenge, seeking to stop his trial by claiming the 
regulations were unconstitutional. Lawyers for Mr Bederev 
argued it was not lawful to put this substance on the 
controlled drug list because there were no principles and 
policies guiding the introduction of such rules. In particular, 
it was argued that the decision to ban a particular drug 
was a matter to be considered by the Oireachtas before the 
relevant government minister could formally initiate the ban. 
In May 2014 the High Court rejected this challenge. 
On behalf of the Court of Appeal, Mr Justice Gerard Hogan 
said, given what had been done in relation to the substance 
in this case, it might also be asked whether it would be open 
to the Government to employ the same law to ban other 
types of drugs which are in everyday use and which are 
potentially harmful and liable to be misused such as alcohol 
and tobacco. The Court of Appeal considered the evidence 
of the then Chief Pharmacist at the Department of Health 
and Children before the High Court. She had explained that 
drug and pharmaceutical products were ever changing and 
new products were constantly coming on the market. In 
these circumstances, ‘it would be cumbrous to insist that 
any such new drugs or drug products which were dangerous 
or liable to misuse could only be banned by legislation 
subsequently enacted by the Oireachtas’ (p.13). While 
acknowledging this issue, Judge Hogan asked how decisions 
as to the dangers of drugs or misuse came to be decided. 
The central question in the appeal was whether the 1977 Act 
contained sufficient principles and policies to inform such 
questions (p.23).
The Court of Appeal looked to the long title of the Act 
for guidance. This declares the purpose and object of the 
1977 Act is ‘to prevent the misuse of certain dangerous or 
otherwise harmful drugs’ (p. 23). Judge Hogan then listed 
a series of key questions that he ultimately would conclude 
were not sufficiently addressed in the Act:
 ■ How is it to be determined which of these dangerous or 
harmful drugs are to be controlled and which are not? 
 ■ How can it be determined which drugs are ‘dangerous’, 
and to whom? 
 ■ Is this standard to be measured by reference to the 
general public? Or would it suffice that the drug in 
question would be dangerous if consumed or used  
by certain sectors of society such as children or  
young adults?
 ■ By what standards are the questions of whether 
particular drugs are ‘harmful’ and liable to be ‘misused’ 
to be assessed and determined?
 ■ What levels of ‘harm’ and ‘misuse’ need to be established 
before an order could properly be made (p.24)
Summing up for the Court of Appeal, Judge Hogan stated 
that the unavoidable conclusion was that s.2.2 purports to 
vest in the Government what, in the absence of appropriate 
principles and policies in the legislation itself, ‘are in truth 
law-making policies’ (p. 30). As a result of the judgement, 
all substances controlled by means of Government Orders 
made under s.2(2) of the Misuse of Drugs Act 1977 ceased 
to be controlled with immediate effect, and their possession 
ceased to be an offence. These substances included ecstasy, 
Misuse of Drugs (Amendment) Act 2015
4. Department of Justice and Equality (2010) Criminal Justice 
(Psychoactive Substances) Bill 2010: regulatory impact analysis 
Dublin: Department of Justice and Equality.  
http://www.drugsandalcohol.ie/15465/ 
5. Reuter P (2011) Options for regulating new psychoactive 
drugs: a review of recent experiences London: UK Drug Policy 
Commission. http://www.drugsandalcohol.ie/15458/ 
6. Ryall G and Butler S (2011) The great Irish head shop  
 
controversy Drugs: education, prevention and policy (18/4): 
303–311. http://www.drugsandalcohol.ie/15360/ 
7. ‘Call to halt legal highs ban based on “flawed” Irish 
system’ http://www.bbc.com/news/uk-33226526. See also 
Parliamentary submission by the UK drug-reform charity 
Release ‘Proposed amendments to Psychoactive Substances 
Bill for Committee Stage’ http://www.release.org.uk/
publications/release-transforms-submission-home-affairs-
select-committees-short-inquiry-psychoactive 
Judging prohibition (continued)
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National Drugs Strategy (NDS) 2009 – 
2016: progress in 2014
The progress report provides a narrative account of progress 
against each action in the NDS 2009–2016, for the year 
2014.1 It indicates which actions under each pillar have been 
completed, where work is in under way, and where actions 
have been delayed or abandoned (Table 1). 
Supply reduction 
Under this pillar, most progress has been made in relation 
to local supply reduction initiatives, and compliance with 
EU-level obligations and operations. Local initiatives included 
establishing and supporting appropriate drug networks 
and ensuring drug issues are included in the work of Joint 
Policing Committees, developing frameworks for tackling 
drug-related intimidation in the community, targeting adults 
in the drug trade who use children to engage in illegal drug-
related activities, improving drug-related security in prisons 
and introducing a presumptive drug testing regime. 
Work is under way in relation to several policy initiatives – 
legislation on drugs and driving, licensing laws to combat 
sale or supply of alcohol to persons under the age of 18, the 
Drug Court and the Forensic Science Laboratory. 
Two capital projects have been put on hold owing to the 
difficult economic situation – developing an integrated 
system to track the progression of offenders with drug-
related offences through the criminal justice system, and 
building a new Forensic Science Laboratory.
Prevention 
Actions under this pillar relate to both illicit drugs and 
alcohol. Most progress has been made with regard to setting 
up education programmes and drug policies in schools, 
including support mechanisms in DEIS schools, and with 
regard to youth interventions and facilities in out-of-school 
settings, and developing online prevention and help services. 
Work is under way developing programmes targeting 
families experiencing difficulties owing to drug/alcohol use 
and the children of drug users, and also selective prevention 
measures to reduce under-age and binge drinking. 
The adoption of the National Substance Misuse Strategy 
has led to a delay in the development of a framework  
of targeted prevention and education interventions  
using a tiered approach, and in the implementation of a 
uniform set of drugs and alcohol education standards – 
while the methodologies are re-assessed to ensure they 
are still appropriate. It has also delayed the promotion 
of substance misuse policies and development of brief 
interventions in the informal education sector, tertiary 
institutions, workplaces, and youth, sport and  
community organisations.
Treatment and rehabilitation
Treatment and rehabilitation services continue to be 
developed on an ongoing basis, including both expanding 
the range of services and the groups with specific needs 
being targeted, for example families of drug users, drug 
users in prisons, and vulnerable groups such as travellers, 
LGBTs, new communities and sex workers. A clinical and 
organisational governance framework for all treatment and 
rehabilitation services has been developed. 
Work is reported to be well under way with regard to 
developing treatment guidelines for treating blood-borne 
viruses, and training programmes for all involved in the 
provision of substance misuse treatment services. Policies 
and procedures for referrals of under-18 service users 
who are showing signs of substance use, and for young 
people arrested by the Gardaí, are also being developed. 
In response to the issue of drug-related deaths, a naloxone 
demonstration project has been rolled out.
A statutory regulatory framework for the provision of 
counselling within substance misuse services has been 
delayed because counselling is not one of the 12 health 
and social care professions designated under the Health 
and Social Care Professionals Act 2005. A statutory 
consultation process is now under way on the possible 
designation of counsellors and psychotherapists for 
regulation under the 2005 Act.
Table 1: Progress in 2014 against actions in NDS 2009–2016
Pillar Actions
Total  
number
Completed or 
ongoing
Under way Delayed or 
abandoned
Supply reduction 17 11 4 2
Prevention 13 7 3 3
Treatment and rehabilitation 25 11 10 4
Research and information 8 2 3 3
benzodiazepines and new psychoactive substances, so-called 
‘headshop drugs’. Following an emergency sitting of the 
Oireachtas, new legislation was passed and then signed into 
law by the President within forty-eight hours. 
(Johnny Connolly)
1. Misuse of Drugs (Amendment) Act 2015 (No 6 of 2015) 
Downloaded 6 October 2015 at http://www.oireachtas. 
ie/viewdoc.asp?fn=/documents/bills28/bills/2015/2115/
document1.htm 
2. Hogan, Mr Justice Gerard, Court of Appeal (2015, 10 March) 
Bederev–v-Ireland, The Attorney General and the Director 
of Public Prosecutions. Dublin: Courts Service. http://www.
drugsandalcohol.ie/24355/
3. Maddox N (2004, 7 January) Legislation by delegation 
- the principles and policies test in Irish law Irish Law 
Times (22/293). Available at SSRN: http://ssrn.com/
abstract=1532885
Misuse of Drugs (Amendment) Act 2015 (continued)
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Benzodiazepine use among young 
people attending a treatment centre
Benzodiazepines are commonly-prescribed drugs used 
for a wide range of conditions and symptoms including 
anxiety, insomnia and epilepsy. They have short-term side-
effects, e.g. impairment of perception of risk, restlessness, 
agitation, anxiety and delusions, and long-term use can lead 
to dependence. The 2010/2011 National Drug Prevalence 
Survey found that lifetime use of benzodiazepines among 
15–34-year-olds in Ireland was 35.7%, an increase on 
lifetime use at the time of the previous survey.1
The results reported here describe the characteristics of young 
people attending the Matt Talbot Services in Cork between 
January 2005 and August 2011, and their patterns of drug 
use, in particular benzodiazepines.2 The authors retrospectively 
reviewed client notes and extracted data of interest from the 
notes. Collecting complete data for each participant on all the 
variables of interest was not possible, and so the denominators 
for many characteristics vary depending on the completeness 
of the data relating to the individual variables. As a result, the 
proportions reported in the following account vary.
The number of clients referred to the service increased over 
the years, from two in 2005 to 49 in 2010. A total of 198 
client files were included in the study. Almost all the clients 
included in the study were male (98%). This is because 
originally the service was just for males and only started to 
accept females for treatment in 2010. The average age of 
clients was 16.4 years (range 13 to 21 years). Most clients 
(55/113, 49%) were referred by the Department of Justice, 
either through Juvenile Liaison Officers or Probation Officers. 
Almost all (182/187, 99%) had ever drunk alcohol, with 
half starting at 13 years or younger. After alcohol, most had 
also used cannabis (170/181, 94%) and tobacco (153/165, 
93%). The next most prevalent drug ever used was cocaine 
(88/162, 54%) and then benzodiazepines (80/157, 51%). 
Of the 80 clients who reported ever using benzodiazepines, 
one third (28/80, 35%) had used them at least once a week, 
and half (43/77, 56%; data on time of last use were not 
available for three) had used them in the previous month 
(classified as regular users). 
The average age of first use of benzodiazepines was  
14.9 years. 
The characteristics of regular benzodiazepine users were 
compared with non-regular users. Regular users were 
significantly more likely to be regular users of other drugs. 
There were also statistically significant differences between 
behavioural and physical symptoms. Regular users were 
more likely to report paranoia, loss of interest in sports or 
hobbies, attention-seeking behaviour, pale/white skin, and 
vomiting. Skin pallor is well-known to be associated with 
benzodiazepine withdrawal and can last several weeks.
The study has limitations. Information was missing for many 
of the variables because data were extracted retrospectively 
from client notes so the results are not comprehensive. More 
data on psychosocial and clinical systems, which could have 
been collected through a tailored questionnaire, would have 
helped to provide a more comprehensive understanding of 
the clients. 
The authors note that benzodiazepines had been used by 
many of the young people attending the service over the 
period and that many of them were regular users. Regular 
users were more likely to suffer from known side-effects of the 
drug such as paranoia. The authors urge greater awareness 
among health professionals of the acute and chronic negative 
consequences associated with benzodiazepine use in young 
people as described in their study.
(Suzi Lyons)
1.  National Advisory Committee on Drugs (NACD) & Public 
Health Information and Research Branch (PHIRB) (2011) 
Drug use in Ireland and Northern Ireland: first results from the 
2010/11drug prevalence survey. Bulletin 1. Dublin: NACD & 
PHIRB. http://www.drugsandalcohol.ie/16450
2.  Murphy K, Byrne S, McCarthy S, Lambert S, and Sahm L 
(2014) Benzodiazepine use among young attendees of 
an Irish substance treatment center. Journal of Addiction 
Medicine 8 (3): 199–204. http://www.drugsandalcohol.
ie/22656/
Research and information
In line with the EU Early Warning System, a communication 
protocol for notification of drug use emergencies has been 
developed in Ireland. The five key epidemiological indicators 
relating to drug use (prevalence in general population, 
prevalence and patterns of use of specific drugs, drug 
treatment demand, drug-related deaths and infectious 
diseases) and the associated data collection systems are also 
all under continuous development.
Work is under way on the development of indicators 
for harm reduction, public expenditure and drugs and 
crime, and of a system for monitoring problem substance 
(including alcohol) use among those presenting to hospital 
emergency departments, and on the roll-out of unique 
identifiers under the Health Identifiers Act 2014.
 
While the National Advisory Committee on Drugs and 
Alcohol (NACDA) is currently overseeing a study to estimate 
the prevalence of children residing with substance-misusing 
parents, and the conduct of two drug prevalence surveys (in 
the general population and the prevalence of opioid use), 
it has been unable to conduct rehabilitation research owing 
to lack of a researcher and a rehabilitation research budget. 
Work on disseminating research findings and models of best 
practice has also been hampered by lack of research staff 
and a reduced budget. The reform of the Coroner Service 
has also had to follow a more gradual, cost-neutral approach 
owing to the difficult national economic situation. 
(Brigid Pike)
1.  Department of Health (2015) National Drugs Strategy 
2009-2016: progress report to end 2014. http://www.
drugsandalcohol.ie/23935/ 
National Drugs Strategy (continued)
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Changes to the NDTRS form for 2016 
data collection
In order to comply with reporting requirements for the 
EMCDDA,1 the NDTRS form for 2016 has been extensively 
changed and updated. As part of this process the NDTRS 
team also took the opportunity to revise and update the 
remaining questions to ensure that data important at a 
national level are captured as well 
The revised form is shown on pages 15–18. 
Spotlight on selected new and revised questions
Q2b Integrated individual health identifier (IHI) 
The IHI number is included in preparation for the 
implementation of the IHI in the future although it is not  
yet available.2 
Q3 – Q3a Sex: self-defined gender identity and Q3b Self-
defined sexual orientation 
The rationale for collection of data on self-defined gender 
and sexuality comes from specific actions contained in the 
current National Drugs Strategy (NDS).3 A key theme that 
emerged throughout all stages of the consultation process 
for the NDS was the requirement to focus on the needs 
of specific communities and help them to access services 
tailored according to their needs. In addition to the needs  
of prisoners, Travellers, new communities and homeless 
people, the other key group identified was lesbian, gay,  
bi-sexual and transgender (LGBT) people. This new  
question will provide data to allow Actions 28 and 44 of  
the NDS to be assessed and measured in the future in 
relation to LGBT people. 
Q6 Number of children
The revised form will allow the number of children (under 
and over 18 years of age) that the client has to be recorded. 
This new question will enable information to be collected by 
age bands: less than five; five to 17; 18 and older. It will also 
allow the living arrangements of the children to be captured 
for the first time. This means that in the future, the number 
of children living with problem drug or alcohol users can be 
enumerated. This will assist with estimating the number of 
young and older children at risk of hidden harm.4 
Q11a, Q11b and Q11c – Ethnicity
The NDTRS form has been updated to match the 
ethnicity questions asked by the Central Statistics Office 
(CSO). Instead of nationality, country of birth will now 
be recorded. The terminology for the options on ethnic/
cultural background have been standardised with the CSO 
terminology and the option of Roma has been added. A 
new question on the language spoken at home (other than 
English or Irish) has been included. Information garnered 
through these questions should assist with planning services 
for new communities.
Q13 Main reason for referral
The list of process addictions that can be recorded has been 
increased and now includes gambling, spending, eating 
disorders, sex or porn addiction, and internet/gaming. 
Q25a Current problem drug(s)
Four additional problem drugs can now be recorded instead 
of three. This should allow better understanding of trends in 
polydrug use.
Q29d Number of previous alcohol detoxes
In order to understand better the harm of problem alcohol 
use, a new question looks to ascertain the number of alcohol 
detoxes a client has undergone. The need for alcohol 
detoxification can be an indicator of chronic harm caused by 
problem alcohol use. 
Risk behaviour – Q30c Frequency of injecting
 In line with requirements for reporting to Europe, 
information on the time period during which the client last 
injected has been expanded: 
 ■ injected in the past 30 days; 
 ■  injected in the past 12 months, but not in the  
past 30 days; 
 ■ injected, but not in the past 12 months; 
 ■ Service user did not wish to answer. 
Risk behaviour – Q30d and Q30e Sharing of needles and 
syringes and/or other drug paraphernalia
In order to comply with reporting to Europe, the questions 
on sharing drug equipment have now been separated out: 
sharing of needles and syringes is to be reported separately 
from other drug paraphernalia, e.g. straws, pipes etc. The 
time period for any sharing will also now be recorded: 
shared in the past 30 days; shared in the past 12 months, 
but not in the past 30 days; shared, but not in the past 12 
months; service user did not wish to answer
Q32a Treatment interventions
Services will now be able to record the start date, end 
date and number of sessions of key working given during 
a client’s treatment. Detoxification from specific additional 
drugs can also now be recorded including ‘Z’ drugs. There 
is also space to specify other types of drugs not listed on the 
form, e.g. cannabis.
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Q34 Condition and progress of client at discharge or 
when last seen
The revised form will try to capture more meaningful 
information on the condition, outcomes and progress of 
clients when they leave the service (for whatever reason). 
Information about changes in drug and/or alcohol use, 
about progress with their care plan (if applicable), and about 
engagement with other services on the road to recovery 
can be collected. There is also an option to ‘specify’ other 
outcomes important to different services, which will be 
monitored over the first year of data collection. Subsequent 
versions of the form will be updated and revised, where 
possible, to reflect important emerging measures.
Phased roll-out of training
The NDTRS team will start a phased roll-out of training 
for the new form in the autumn of 2015. The team will 
contact individual services to let them know the timetable 
for training. However, all services will receive the new 
forms, along with in-depth revised protocols, in the post in 
December 2015 in order to start completing them from 1 
January 2016. 
The NDTRS team is aware of the considerable work involved 
in collecting these data, and we would like to take this 
opportunity to thank all the services for their invaluable input 
and cooperation. The NDTRS team would also like to thank all 
those who participated in the pilot of the revised form.
New on-line database ‘LINK’
In parallel to the revision of the hard-copy form, the 
NDTRS team are redeveloping the NDTRS database. The 
new system, called ‘LINK’, will be web-based, allowing 
services to enter their data directly onto the on-line system, 
and ultimately enabling more timely and accessible data. 
Information about ‘LINK’ and its roll-out will be published in 
the winter edition of Drugnet Ireland.
If you have any queries before this time please contact the 
team at ndtrs@hrb.ie.
(Suzi Lyons)
1.  EMCDDA (2012) Treatment demand indicator (TDI) standard 
protocol 3.0: Guidelines for reporting data on people entering 
drug treatment in European countries. Lisbon: EMCDDA. 
http://www.emcdda.europa.eu/publications/manuals/tdi-
protocol-3.0
2.   For more information on the IHI, go to http://www.hiqa.ie/
healthcare/health-information/health-identifiers
3.   Department of Community, Rural and Gaeltacht Affairs 
(2009) National Drugs Strategy (interim) 2009 – 2016. 
Dublin: Department of Community, Rural and Gaeltacht 
Affairs. http://www.drugsandalcohol.ie/12388/
4.   Health Service Executive, Child and Family Services (2014) 
Hidden harm stakeholder consultation, 28 January 2014, 
Radisson Hotel Sligo. http://www.drugsandalcohol.ie/22374/
NDTRS data collection 2016 (continued)
Aodhán Ó Ríordáin TD, Minister of State for the Drugs Strategy and Dr Siobhan O’Halloran, Chief Nursing Officer Department 
of Health with HRB staff on recent visit to the Health Research Board
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Please check information is legible on carbon copies.
Surname
Address
Eircode
A.
 
Administrative
 
details PLEASE COMPLETE USING A BALL POINT PEN
Forename
1b. Type1a. Centre 2b. IHI  
1. Male
Country
2. Female 3. Transgender3a. Sex (circle)
1. Heterosexual 2. Homosexual
4. 
99. Not known
 Did not wish to answer this question
3. Bisexual
3b. Self-defined sexual orientation  (circle)
8a. Area of residence
(See pink book or Appendix 1)
10. Employment status 
(if yes, specify)
(circle)
1. In paid employment 2. Unemployed
3. Training course      4. Student
5. Housewife/husband     6. Retired/unable to work
8. Other (specify)
9. Not known
9b. Age left primary or secondary school for the first time
(not third level) (years, or circle code below) 
01. Never went to school
88. Still at school
99. Not known
9a. Education: highest level completed to date  (circle)
0. Primary level incomplete 1. Primary level
2. Junior cert     3. Leaving cert
4. Third level     5. Never went to school
9. Not known
11a. Country of Birth (circle, if other please specify)
1. Ireland     2. Other     99. Not known
11b. Ethnic / cultural background (circle)
1.  Irish 
10. Do not wish to answer this question
2.  Irish Traveller
3. Any other white background 4.  Black African 
5. Any other black background
6. Asian Chinese 7. A
99. Not known
ny other Asian background
8. Other, including mixed background 
11. Roma 
 
4a. Date of birth
5. Living with whom (circle)
6. Number of children
1. Alone     
Total number of children     
2. Parents/family
3. Friends     4. Partner (alone)
5. Partner & child(ren)  6. Alone with child(ren)
8. Foster care    7. Other 9. Not known
B. Demographic details
8c. City/county
8b.
(see appendices 1/2)
CCA Day Month Year
4b. Age Years
Number living with client
Number in care
Number living with other parent
Number living elsewhere
Living status not known
11c. Language other than English or Irish at home?
(circle)
1. Yes    2. No
   
7. Living where  (circle)
1. Stable accommodation
3. Homeless
5. Prison 6. Institution (residential care/halfway house)
4.  Unstable accommodation
9. Not known
(specify)
12. Date of referral
15. Date of initial assessment
13. Main reason for referral   
 
Alcohol
  Drug
Concerned person
  
Other problem
14. Source of referral (circle)
1. Self    2. Family  3. Friends
4. Other drug treatment centre 5. General practitioner
6. Acute hospital service excluding emergency dept.
7. Social services/Community services
8. Court/probation/police   10. Outreach worker
13. Prison12. School or college  
14. Employer 16. Emergency Department (ED)
17. Mental 18. Needle Exchange health professional
99. Not
 
known
C. Referral/assessment details
Day Month Year
Day Month Year
(specify)
20a. Ever received any opiate substitution before (excluding this current treatment)
20b. Age first received any opiate substitution 
(excluding this current treatment)
1. Previously received 2. Never received  99. Not known18. Number of times started treatment in this this year (Jan-Dec)
(Enter 1, if first time this year)
 
Times
Years
D. Treatment details
E. Drug use
17.  Where client is suitable for treatment (circle one)
1. Treatment offered with this centre and client accepted
10. Treatment offered with this centre and client DID NOT accept
3. Client did not fulfill criteria to commence treatment
4. Client commenced treatment with another centre
5. Service unable to contact / locate client
7. Client sent to prison 8. Client died
11. Other (specify)
pl
ea
se
 fo
ld
 h
er
e
pl
ea
se
 fo
ld
 h
er
e
F. Risk behaviour
years 30b. If yes, age first injected
30c. Frequency of injecting (circle one only)
31. History of viral screening (one tick per column)
1. Injected in the last 30 days
2. Injected in the last 12 months but not in the last 30 days
3. Injected but not in the last 12 months
4. Client did not wish to answer 99. Not known
30d. Ever shared needle and syringes (circle one only)
2. Never shared
Brief intervention
Individual counselling
Group counselling
Group education/awareness 
programme
Individual education/
awareness programme
Medication free therapy
Complementary therapies
Social and/or occupational
reintegration
Family therapy
Structured after care 
programme
Community detox
Strengthening family 
programme
Methadone substitution
Buprenorphine/naloxone
substitution
Detox from alcohol
Detox from benzodiazepines
Detox from heroin
Detox from methadone
Detox from other drug
Specify:        
Detox from “Z” drugs
Case manager appointed
Care plan
Key working
Psychiatric treatment
1. Shared in the last 30 days
3. Shared in the last 12 months but not in the last 30 days
4. Shared but not in the last 12 months
5. Client did not wish to answer 99. Not known
30e. Ever shared any other  drug paraphernalia (excluding needles and syringes)
(circle)
2. Never shared
1. Shared in the last 30 days
3. Shared in the last 12 months but not in the last 30 days
4. Shared but not in the last 12 months
5.
1.
2.
3.
4.
99.
Client did not wish to answer 99. Not known
30a. Ever injected (circle) 1. Yes 2. No  9. Not known
 
29a. Please specify the 
(circle all that apply)
preferred
standard drinks
types of alcohol consumed 
2. Beer 3. Spirits 4. Wine 5. Fortified wine 6. Cider 7. Alcopops
8. Other specify
29c. Please categorise the extent of the drinking problem (circle)
2. Hazardous drinker 3. Harmful drinker   4. Dependent drinker
29d. Number of previous alcohol detoxes  
If alcohol is listed as a problem drug at Q21-Q25, please complete
Q29a to Q29d, otherwise go to Q30a.  
If no or unknown,
If unknown, Code 99
 go to Q30e.
Standard drinks
H. Exit details
29b. How many  were consumed
on a typical drinking day over the past month? 
(if none write 0)
(if none write 0, if unknown 99)
(If none write 0)
18 yrs or Over5 - 17 yrsUnder 5 yrs
16. Assessment outcome (circle one)
1. Suitable for treatment in any drug/alcohol service
3. Referred to another site, no intervention provided in this centre
2. Unsuitable for drug or alcohol treatment
4. Psychiatric assessment only
If 2, 3, 4 STOP  and return form to HRB. 
If 1  continue form, otherwise STOP and return form to HRB. 
centre 
years 
years 
(if not applicable code 88)
26.  Age first used any drug 
(excluding alcohol and tobacco)
(excluding alcohol and tobacco)
 
27.  Specify first drug ever used 
Route of administration
1. Inject
2. Smoke
3. Eat/Drink
4. Sniff/snort
6.
7.
 Rectal
9.
 Topical
 Not known
21. Main drug
3. Daily
6. 4-6 days per week
7. 2-3 days per week
1. Once a week or less
4. No use in the past month
9. Not known
Frequency of use in past month
a. Current problem drug(s) 
including alcohol (write in words)
b. Route of
administration
(use code)
c. Frequency of
use in last
month (use code)
d. Age at first
use (years, if
unknown 99)
22. Drug 2
23. Drug 3
24. Drug 4
25. Drug 5
(e.g. straws, foil, pipes)
Hepatitis C Hepatitis B HIV
Never tested
Tested in the past 12 months
Tested but not in the last 12 months
Client did not wish to answer
Not known
G. Activity details
32a.
 
Treatment interventions
32b. Date
started
32d. Number of
sessions/visits
32c. Date 
finished
(or of last visit) 32a. Treatment interventions
32b. Date
started
32d. Number of
sessions/visits
32c. Date 
finished
(or of last visit)
33a. Exit details
1. Treatment completed
 
2. Transferred/referred to another drug/alcohol treatment service
4. Client declined further treatment
5. Client did not return for appointments (no show/DNA)
7. Released from prison but not linked to other treatment service
9. Sentenced to prison
14. Prison to prison transfer
12. No longer lives in the area
8. Died
10. Other (specify)
(circle)
6. Premature exit for non-compliance. Specify reason (circle one)
1. Drug taking   2. Violent behaviour   3. Illegal activities
5. Alcohol taking   4. Breaking service contract
33b. Transfer or referral
1. Transferred/referred to another centre for additional/continued alcohol or drug treatment
(specify centre)
(circle)
34. Condition of client at discharge or when last seen
33c. Please specify the number of family members or significant others 
(who were not treated for a personal addiction) involved in this treament
(circle all that apply)
1. Drug free
2. Drug use unchanged
3. Drug use increased
5. Abstaining from alcohol
4. Drug use reduced
6. Alcohol consumption unchanged
7. Alcohol consumption increased
11. Engaging with care plan
12. Disengaged from care plan
13. Care plan gaps and blocks identified
35. Date of final discharge or transfer
Day Month Year
E. Drug use, continued 
  
 
Please write 0 if none
14. Engaging with other services (e.g. housing, education)
15. Engaging with other therapeutic services (e.g. self help groups, AA)
16. Engaging in other unstructured aftercare
99. Not known
28. Was it difficult to assess which 
was the main problem drug?
1. Yes 2. No
Drugs
Alcohol
19. History of treatment (answer both questions, please tick)
Never treated Previously treated
Treatment status 
unknown
Age first treated
(years, if unknown 99)
 99. Not known
17. Other (specify)
2a. Client number
Circle ONLY one option
Multi component model
8. Alcohol consumption reduced
10. Substantially reached priority
goals of care plan
 
1.
2.
3.
4.
If unknown, Code 99
NDTRS
National Drug Treatment Reporting System, Health Res arch Board.
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details PLEASE COMPLETE USING A BALL POINT PEN
Forename
1b. Type1a. Centre 2b. IH  
1. Male
Country
2. Female 3. Transgender3a. Sex (circle)
1. Heterosexual 2. Homosexual
4. 
99. Not known
 Did not wish to answer this question
3. Bisexual
3b. Self-defined sexual orientation  (circle)
8a. Area of residence
(See pink book r Appendix 1)
10. Employment s atus 
(if yes, specify)
(circle)
1. In paid employment 2. Unemployed
3. Training course    4. Student
5. Housewife/husband    6. Retired/unable to work
8. Other (specify)
9. Not known
9b. Age l ft primary or secondary school for the first time
(not third level) (years, or ci cle code b low) 
01. Nev r went to school
88. Still at school
99. Not known
9a. Education: highest lev l complet d to date  (circle)
0. Primary lev l incomplete 1. Primary lev l
2. Junior cert     3. Leaving cert
4. Third lev l     5. Nev r went to school
9. Not known
11a. Country of Birth (circle, if other please pecify)
1. Ireland     2. Other     99.Not known
11b. Ethnic / cult ral background (circle)
1.  Irish 
10. Do not wish to answer this question
2.  Irish Traveller
3. Any other white background 4.  Black African 
5. Any other black background
6. Asian Chines 7. A
99. Not known
ny other Asian background
8. Other, including mixed background 
11. Roma 
 
4a. Date of birth
5. Living with whom (circle)
6. Number of children
1. Alone     
Total number of children     
2. Parents/family
3. Friends     4. Partner (alone)
5. Partner & child(ren)  6. Alone with child(ren)
8. Foster care    7. Other 9. Not known
B. Demographic details
8c. City/county
8b.
(see appendices 1/2)
CCA Day Month Year
4b. Age Years
Number living with client
Number in care
Number living with other parent
Number living els where
Living status not known
11c. Language other than English or Irish at home?
(circle)
1. Yes    2. No
   
7. Living wher  (circle)
1. Stable accommodation
3. Homeless
5. Prison 6. Institution (residential care/halfway house)
4.  Unstable accommodation
9. Not known
(specify)
12. Date of referral
15. Date of initial sse sment
13. Main reason for referral   
 
Alcoh l
  Drug
Concerned person
  
Other p oblem
14. Source of referral (circle)
1. Self    2. Family  3. Friends
4. Other d ug treatment centre 5. Gen ral practitioner
6. Acute hospital service excluding emergency dept.
7. Social services/Community services
8. Court/probation/police   10. Outreach worker
13. Prison12. School r colleg   
14. Employer 16. Emergency Department (ED)
17. Mental 18. Needl  Exchange health professional
99. Not
 
known
C. Ref rral/assessment details
Day Month Year
Day Month Year
(specify)
20a. Ever rec ived any opiate substitution before ( xcluding this current treatment)
20b. Age first rec ived any opiate substitution 
(excluding this current treatment)
1. Previously rec iv d 2. Nev r rec iv d  99. Not known18. Number of times started treatment in this this year (Jan-Dec)
(Enter 1, if first time this year)
 
Times
Years
D. Treatment details
E. Drug use
17.  Wher  client is suitable for t eatment (circle one)
1. Treatment offered with is centre and client accepted
10. Treatment offered with is centre and client DI  NOT accept
3. Client did not fulfill criteria to commence treatment
4. Client commenced treatment with another centre
5. Service unable to contact / locate client
7. Client sent to prison 8. Client die
11. Other (specify)
pl
ea
se
 fo
ld
 h
er
e
pl
ea
se
 fo
ld
 h
er
e
F. Risk behaviour
years 30b. If yes, age first injected
30c. Frequency of injecting (circle one only)
31. History of viral screening (one tick per column)
1. Injected in the last 30 days
2. Injected in the last 12 months but not in the last 30 days
3. Injected but not in the last 12 months
4. Client did not wish to answer 99. Not known
30d. Ever shared needle and syringes (circle one only)
2. Nev r shared
Brief intervention
Individual counselling
Group counselling
Group education/aw ren ss 
programme
Individual education/
aw ren ss programme
Medication free therapy
Complementary therapies
Social nd/or ccupational
reintegration
Family therapy
Structured after care 
programme
Community detox
Strengthening family 
programme
Methadone substitution
Buprenorphine/nalox ne
substitution
Detox from alcoh l
Detox from benzodiazepines
Detox from heroin
Detox from ethadone
Detox from other d ug
Specify:      
Detox from “Z” drugs
Case man ger appointed
Care plan
Key working
Psychiatric treatment
1. Shared in the last 30 days
3. Shared in the last 12 months but not in the last 30 days
4. Shared but not in the last 12 months
5. Client did not wish to answer 99. Not known
30e. Ever shared any other  drug par phernali  (excluding eedl s and syringes)
(circle)
2. Nev r shared
1. Shared in the last 30 days
3. Shared in the last 12 months but not in the last 30 days
4. Shared but not in the last 12 months
5.
1.
2.
3.
4.
99.
Client did not wish to answer 99. Not known
30a. Ever injected (circle) 1. Yes 2. No  9. Not known
 
29a. Please specify the 
(circle all tha  apply)
preferred
standard drinks
types of alcoh l consumed 
2. Beer 3. Spirits 4. Wine 5. Fortified wine 6. Cider 7. Alcop s
8. Other specify
29c. Please categorise the extent of the drinking problem (circle)
2. Haz rdous drinker 3. Harmful drinker   4. Dep ndent drinker
29d. Number of previous alcoh l detoxes  
If alcoh l is listed as a problem drug at Q21-Q25, please complet
Q29a to Q29d, otherwise go t  Q30a.  
If no or unknown,
If unknown, Code 99
 go t  Q30e.
Stand rd d inks
H. Exit details
29b. How many  wer  consumed
on a typical drinking day over the past month? 
(if none write 0)
(if none write 0, if unknown 99)
(If none write 0)
18 yrs or Over5 - 17 yrsUnder 5 yrs
16. Asse sment outcome (circle one)
1. Suitable for treatment in any drug/alcoh l service
3. Referr d to another site, no intervention provide  in this centre
2. Unsuitable for d ug or alcoh l treatment
4. Psychiatric asse sment only
If 2, 3 4 STOP  and return form to HRB. 
If 1  conti ue form, otherwise STOP and return form to HRB. 
centre 
years 
years 
(if not applicable code 88)
26.  Age first used any drug 
(excluding alcoh l and tobacco)
(excluding alcoh l and tobacco)
 
27.  Specify irst drug ev r used 
Route of administration
1. Inject
2. Smoke
3. Eat/Drink
4. Sniff/snort
6.
7.
 Rectal
9.
 Topical
 Not known
21. Main drug
3. Daily
6. 4-6 days per week
7. 2-3 days per week
1. Once a week or less
4. No use in the past month
9. Not known
Frequency of use in past month
a. Current problem drug(s) 
including alcohol (write n words)
b. Route of
administration
(use code)
c. Frequency of
use in last
month (use code)
d. Age at first
use (years, if
unknown 99)
22. Drug 2
23. Drug 3
24. Drug 4
25. Drug 5
(e.g. straws, foil, pipes)
Hepatitis C Hepatitis B HIV
Nev r tested
Tested in the past 12 months
Tested but not in the last 12 months
Client did not wish to answer
Not known
G. Activity details
32a.
 
Treatment interventions
32b. Date
started
32d. Number of
se sions/visit
32c. Date 
finished
(or f last visit) 32a. Treatment interventions
32b. Date
started
32d. Number of
se sions/visit
32c. Date 
finished
(or f last visit)
33a. Exit details
1. Treatment completed
 
2. Transferr d/referr d to another d ug/alcoh l treatment service
4. Client declined further treatment
5. Client did not return for appointments (no show/DNA)
7. Released from prison but not linked to other treatment service
9. Sentenced to prison
14. Prison to prison transfer
12. No l nger lives in the area
8. Died
10. Other (specify)
(circle)
6. Premature exit for no -compliance. Specify reason (circle one)
1. Drug taking   2. Violent behaviour   3. Illegal ctivi es
5. Alcoh l taking   4. Breaking service contract
33b. Transfer or referral
1. Transferr d/referr d to another centre for additional/conti ued alcoh l r d ug treatment
(specify centre)
(circle)
34. Condition of client a discharge or when last een
33c. Please specify the number of family members or significant others 
(who wer  not treated for a personal ddict on) involved in this treament
(circle all tha  apply)
1. Drug free
2. Drug use unchanged
3. Drug use increased
5. Abstaining from alcoh l
4. Drug use r duced
6. Alcoh l consumption unchanged
7. Alcoh l consumption i creased
11. Enga in  with care plan
12. Disenga ed from care plan
13. Care plan gaps and blocks identified
35. Date of final discharge or t ansfer
Day Month Year
E. Drug use, continued 
  
 
Please write 0 if no e
14. Enga in  with other services (e.g. housing, education)
15. Enga in  with other therapeutic services (e.g. self help groups, AA)
16. Enga in  in other unstructured aftercare
99. Not known
28. Was it difficult to asse s which 
was the main problem drug?
1. Yes 2. No
Drugs
Alcoh l
19. History of treatment (answer both questions, please tick)
Never treat d Previously treat d
Treatment status 
unknown
Age first treat d
(years, if unknown 99)
 99.Not known
17. Other (specify)
2a. Client umber
Circle ONLY one option
Multi compone t model
8. Alcoh l consumption reduced
10. Substantially reached prio ty
goals of care plan
 
1.
2.
3.
4.
If unknown, Code 99
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 Did not wish to answer this question
3. Bisexual
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8a. Area of residence
(See pink book or Appendix 1)
10. Employment status 
(if yes, specify)
(circle)
1. In paid employment 2. Unemployed
3. Training course      4. Student
5. Housewife/husband     6. Retired/unable to work
8. Other (specify)
9. Not known
9b. Age left primary or secondary school for the first time
(not third level) (years, or circle code below) 
01. Never went to school
88. Still at school
99. Not known
9a. Education: highest level completed to date  (circle)
0. Primary level incomplete 1. Primary level
2. Junior cert     3. Leaving cert
4. Third level     5. Never went to school
9. Not known
11a. Country of Birth (circle, if other please specify)
1. Ireland     2. Other     99. Not known
11b. Ethnic / cultural background (circle)
1.  Irish 
10. Do not wish to answer this question
2.  Irish Traveller
3. Any other white background 4.  Black African 
5. Any other black background
6. Asian Chinese 7. A
99. Not known
ny other Asian background
8. Other, including mixed background 
11. Roma 
 
4a. Date of birth
5. Living with whom (circle)
6. Number of children
1. Alone     
Total number of children     
2. Parents/family
3. Friends     4. Partner (alone)
5. Partner & child(ren)  6. Alone with child(ren)
8. Foster care    7. Other 9. Not known
B. Demographic details
8c. City/county
8b.
(see appendices 1/2)
CCA Day Month Year
4b. Age Years
Number living with client
Number in care
Number living with other parent
Number living elsewhere
Living status not known
11c. Language other than English or Irish at home?
(circle)
1. Yes    2. No
   
7. Living where  (circle)
1. Stable accommodation
3. Homeless
5. Prison 6. Institution (residential care/halfway house)
4.  Unstable accommodation
9. Not known
(specify)
12. Date of referral
15. Date of initial assessment
13. Main reason for referral   
 
Alcohol
  Drug
Concerned person
  
Other problem
14. Source of referral (circle)
1. Self    2. Family  3. Friends
4. Other drug treatment centre 5. General practitioner
6. Acute hospital service excluding emergency dept.
7. Social services/Community services
8. Court/probation/police   10. Outreach worker
13. Prison12. School or college  
14. Employer 16. Emergency Department (ED)
17. Mental 18. Needle Exchange health professional
99. Not
 
known
C. Referral/assessment details
Day Month Year
Day Month Year
(specify)
20a. Ever received any opiate substitution before (excluding this current treatment)
20b. Age first received any opiate substitution 
(excluding this current treatment)
1. Previously received 2. Never received  99. Not known18. Number of times started treatment in this this year (Jan-Dec)
(Enter 1, if first time this year)
 
Times
Years
D. Treatment details
E. Drug use
17.  Where client is suitable for treatment (circle one)
1. Treatment offered with this centre and client accepted
10. Treatment offered with this centre and client DID NOT accept
3. Client did not fulfill criteria to commence treatment
4. Client commenced treatment with another centre
5. Service unable to contact / locate client
7. Client sent to prison 8. Client died
11. Other (specify)
pl
ea
se
 fo
ld
 h
er
e
pl
ea
se
 fo
ld
 h
er
e
F. Risk behaviour
years 30b. If yes, age first injected
30c. Frequency of injecting (circle one only)
31. History of viral screening (one tick per column)
1. Injected in the last 30 days
2. Injected in the last 12 months but not in the last 30 days
3. Injected but not in the last 12 months
4. Client did not wish to answer 99. Not known
30d. Ever shared needle and syringes (circle one only)
2. Never shared
Brief intervention
Individual counselling
Group counselling
Group education/awareness 
programme
Individual education/
awareness programme
Medication free therapy
Complementary therapies
Social and/or occupational
reintegration
Family therapy
Structured after care 
programme
Community detox
Strengthening family 
programme
Methadone substitution
Buprenorphine/naloxone
substitution
Detox from alcohol
Detox from benzodiazepines
Detox from heroin
Detox from methadone
Detox from other drug
Specify:        
Detox from “Z” drugs
Case manager appointed
Care plan
Key working
Psychiatric treatment
1. Shared in the last 30 days
3. Shared in the last 12 months but not in the last 30 days
4. Shared but not in the last 12 months
5. Client did not wish to answer 99. Not known
30e. Ever shared any other  drug paraphernalia (excluding needles and syringes)
(circle)
2. Never shared
1. Shared in the last 30 days
3. Shared in the last 12 months but not in the last 30 days
4. Shared but not in the last 12 months
5.
1.
2.
3.
4.
99.
Client did not wish to answer 99. Not known
30a. Ever injected (circle) 1. Yes 2. No  9. Not known
 
29a. Please specify the 
(circle all that apply)
preferred
standard drinks
types of alcohol consumed 
2. Beer 3. Spirits 4. Wine 5. Fortified wine 6. Cider 7. Alcopops
8. Other specify
29c. Please categorise the extent of the drinking problem (circle)
2. Hazardous drinker 3. Harmful drinker   4. Dependent drinker
29d. Number of previous alcohol detoxes  
If alcohol is listed as a problem drug at Q21-Q25, please complete
Q29a to Q29d, otherwise go to Q30a.  
If no or unknown,
If unknown, Code 99
 go to Q30e.
Standard drinks
H. Exit details
29b. How many  were consumed
on a typical drinking day over the past month? 
(if none write 0)
(if none write 0, if unknown 99)
(If none write 0)
18 yrs or Over5 - 17 yrsUnder 5 yrs
16. Assessment outcome (circle one)
1. Suitable for treatment in any drug/alcohol service
3. Referred to another site, no intervention provided in this centre
2. Unsuitable for drug or alcohol treatment
4. Psychiatric assessment only
If 2, 3, 4 STOP  and return form to HRB. 
If 1  continue form, otherwise STOP and return form to HRB. 
centre 
years 
years 
(if not applicable code 88)
26.  Age first used any drug 
(excluding alcohol and tobacco)
(excluding alcohol and tobacco)
 
27.  Specify first drug ever used 
Route of administration
1. Inject
2. Smoke
3. Eat/Drink
4. Sniff/snort
6.
7.
 Rectal
9.
 Topical
 Not known
21. Main drug
3. Daily
6. 4-6 days per week
7. 2-3 days per week
1. Once a week or less
4. No use in the past month
9. Not known
Frequency of use in past month
a. Current problem drug(s) 
including alcohol (write in words)
b. Route of
administration
(use code)
c. Frequency of
use in last
month (use code)
d. Age at first
use (years, if
unknown 99)
22. Drug 2
23. Drug 3
24. Drug 4
25. Drug 5
(e.g. straws, foil, pipes)
Hepatitis C Hepatitis B HIV
Never tested
Tested in the past 12 months
Tested but not in the last 12 months
Client did not wish to answer
Not known
G. Activity details
32a.
 
Treatment interventions
32b. Date
started
32d. Number of
sessions/visits
32c. Date 
finished
(or of last visit) 32a. Treatment interventions
32b. Date
started
32d. Number of
sessions/visits
32c. Date 
finished
(or of last visit)
33a. Exit details
1. Treatment completed
 
2. Transferred/referred to another drug/alcohol treatment service
4. Client declined further treatment
5. Client did not return for appointments (no show/DNA)
7. Released from prison but not linked to other treatment service
9. Sentenced to prison
14. Prison to prison transfer
12. No longer lives in the area
8. Died
10. Other (specify)
(circle)
6. Premature exit for non-compliance. Specify reason (circle one)
1. Drug taking   2. Violent behaviour   3. Illegal activities
5. Alcohol taking   4. Breaking service contract
33b. Transfer or referral
1. Transferred/referred to another centre for additional/continued alcohol or drug treatment
(specify centre)
(circle)
34. Condition of client at discharge or when last seen
33c. Please specify the number of family members or significant others 
(who were not treated for a personal addiction) involved in this treament
(circle all that apply)
1. Drug free
2. Drug use unchanged
3. Drug use increased
5. Abstaining from alcohol
4. Drug use reduced
6. Alcohol consumption unchanged
7. Alcohol consumption increased
11. Engaging with care plan
12. Disengaged from care plan
13. Care plan gaps and blocks identified
35. Date of final discharge or transfer
Day Month Year
E. Drug use, continued 
  
 
Please write 0 if none
14. Engaging with other services (e.g. housing, education)
15. Engaging with other therapeutic services (e.g. self help groups, AA)
16. Engaging in other unstructured aftercare
99. Not known
28. Was it difficult to assess which 
was the main problem drug?
1. Yes 2. No
Drugs
Alcohol
19. History of treatment (answer both questions, please tick)
Never treated Previously treated
Treatment status 
unknown
Age first treated
(years, if unknown 99)
 99. Not known
17. Other (specify)
2a. Client number
Circle ONLY one option
Multi component model
8. Alcohol consumption reduced
10. Substantially reached priority
goals of care plan
 
1.
2.
3.
4.
If unknown, Code 99
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Treated problem alcohol use in Ireland, 
NDTRS data 2013
The most recent figures on treated problem alcohol use from 
the National Drug Treatment Reporting System (NDTRS) 
show that a total of 7,549 cases were treated for problem 
alcohol use in 2013, a drop of 12.3% since 2011.1 
The total number of cases has reduced for the last two 
consecutive years for which data are available, from a  
peak of 8,604 in 2011, down to 8,336 in 2012 and 7,549  
in 2013 (Table 1). The number of new cases presenting  
for the first time for treatment also decreased, by 20.8%, 
from 4,520 in 2011 to 3,578 in 2013. Between 2009 and 
2012, the number of cases who returned for treatment 
increased by 19.5% (from 3,524 cases in 2009 to a peak  
of 4,212 in 2012), but between 2012 and 2013, a decrease 
was recorded for this group, from 4,212 to 3,801,  
a drop of 9.8%. 
No specific geographic trends were observed for 2013. 
Twenty-two of the 32 local health offices reported a decrease 
in the number of treated cases, with Cork/North Lee (6.6%), 
Waterford (6.4%) and Donegal (5.9%) reporting the highest 
proportions of cases in 2013. The incidence of treatment for 
problem alcohol use by county between 2009 and 2013 was 
highest in Waterford, Donegal, Sligo, Leitrim and Carlow 
(with each of these counties reporting more than 240 cases 
per 100,000 of the 15–64-year-old population). 
As in previous years, almost one in five (18.8%) of those 
treated for problem alcohol use in 2013 reported problem 
use of at least one other drug. The most common drugs 
used were cannabis, followed by cocaine, benzodiazepines 
and ecstasy. Use of more than one drug increases the 
complexity of cases and can lead to poorer outcomes for  
the patient. 
In 2013, there were no significant changes in the 
sociodemographic characteristics of those treated for 
problem alcohol use compared to 2012:
 ■  Half of those in treatment for problem alcohol use 
started drinking alcohol at 15 years of age or younger. 
 ■  The median age for cases was 40 years.
 ■  While the proportion of cases under the age of 18 
remained small in 2013 (3.0%), the number of new 
cases in that age group fell, from 6.4% in 2010 to 5.0% 
in 2013. 
 ■  The majority of cases, both new (62.6%) and previously 
treated (64.0%), were male. 
 ■  The proportion of cases in employment increased from 
19.7% in 2012 to 21.5% in 2013.
 ■  The proportion of all cases who were homeless in 2013 
was 5.7%. Previously treated cases were more likely to 
be homeless (7.4%) than new cases (3.8%). 
Notwithstanding the increase in the number of treatment 
centres reporting to the NDTRS within the time period, there 
was a decrease in the number of cases treated between 2011 
and 2013. This may reflect a true decrease in the number of 
cases presenting for treatment for problem alcohol use but 
may also reflect reduced levels of participation, or under-
reporting to the NDTRS, or a combination of both. 
NDTRS data for 2004 to 2013 are available on line through 
interactive tables located on the National Documentation 
Centre’s website: http://www.drugsandalcohol.ie/key-info/
(Suzi Lyons)
1.  Health Research Board (2015) Treated problem alcohol  
use in Ireland: figures for 2013 from the National Drug 
Treatment Reporting System. Dublin: National Health 
Information Systems, Health Research Board.  
http://www.drugsandalcohol.ie/23564
Table 1: Number and proportion of cases treated, by treatment status, NDTRS 2009–2013
Treatment status 2009 2010 2011 2012 2013
Number (%)
All cases 7816 7866 8604 8336 7549 
New cases 
4220  
(54.0)
4178  
(53.1)
4520  
(52.5)
4028  
(48.3)
3578  
(47.4)
Previously treated cases
3524  
(45.1)
3583 
(45.6)
3971  
(46.2)
4212  
(50.5)
3801  
(50.4)
Treatment status unknown
72  
(0.9)
105  
(1.3)
113  
(1.3)
96  
(1.2)
170  
(2.3)
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Nursing in contexts of  
marginalised health 
The first Nursing in Contexts of Marginalised Health 
Conference took place in Dublin City University on 11 
September 2015. This timely event, which brought together 
nurses from public health, addiction, academia, policy, and 
other sectors, coincided with the move of the Drugs Policy 
Unit in the Department of Health from Primary Care to the 
Office of the Chief Nursing Officer.
In the morning session, Susan Kent, Deputy Chief Nursing 
Officer, spoke about the important, though often invisible, 
role of nurses and midwives in shaping healthcare policy 
and practice. Diane Nurse, national planning specialist in the 
HSE’s Social Inclusion Unit, provided an overview of activities 
within the Social Inclusion Unit, where three of six staff deal 
primarily with issues of homelessness and drugs. It is hoped 
in the future that services will not be based on specific, often 
marginalised, groups but on a more holistic approach, which 
recognises the people as individuals with particular needs. 
One of the challenges of those working in social inclusion is 
defining and demonstrating outcomes. Commissioning must 
be evidence- and needs-based, but outcomes tend to be 
long-term.
This theme was continued in the afternoon session by Linda 
O’Driscoll, Drug Treatment Court Nurse Liaison. The aim 
of the Drug Court is to prevent recidivism. Although only 
a small proportion graduate from the programme, Linda 
sees improvements in everyone who takes part. Many have 
chaotic lives, so demonstrating changes in their behaviour 
and better management of their daily lives is a positive 
outcome that may not be officially recognised. The Liaison 
Nurse supports clients through her role as advocate and 
expert to the team and Judge in all aspects of treatment.
Aoife O’Driscoll, policy officer at the National Adult 
Literacy Agency (NALA), spoke about removing barriers in 
healthcare, especially the medical language used by health 
practitioners when speaking to clients. She advocates using 
plain English rather than medical ‘jargon’ whenever possible 
and ensuring that clients understand their treatment plans. 
The panel discussion that closed the conference 
acknowledged the complexities inherent in managing 
concurrent marginalisations. Participants believed that 
poor information-sharing, large caseloads and professional 
isolation were having negative impacts on their nursing 
work. It was agreed to maintain the momentum generated 
at the conference by creating a website and uploading the 
conference presentations and setting up a forum, and it 
is hoped to develop a nurses group that will continue to 
advocate for change on behalf of the marginalised in society.
The HRB’s National Drugs Library presented a poster (see 
image on this page) at the conference to show those 
working with marginalised groups that the National Drugs 
Library is a physical library that is open to the public and 
provides access to our books, journals and databases, 
though most people access our resources through our 
website www.drugsandalcohol.ie 
(Mary Dunne & Mairea Nelson)
Mairea Nelson, Mary Dunne and Brian Galvin who work in the 
HRB’s National Drugs Library
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Predicting retention in MMT in Ireland
A cross-sectional study of clients attending a large 
methadone clinic in Dublin was conducted in March 2012, 
with the aim of identifying the factors associated with 
relapse from methadone maintenance treatment (MMT) and 
the reasons for the relapse.1
Almost two thirds (189, 63%) of the total 300 clients 
attending the clinic in March 2012 participated in the study. 
A researcher administered a questionnaire collecting data on 
demographic characteristics and clinical factors and asked 
a series of open-ended questions regarding reasons for 
breaking treatment. Participants were categorised into two 
groups: those who had had a break in their MMT (n=87, 
46%) and those with no break in their MMT (n=102, 54%). 
The demographic profile of both groups was relatively similar 
(Table 1). The majority were male and single, and there was 
a very high level of unemployment in both groups. A higher 
proportion of those with a break in MMT were homeless 
(7.6% versus 1.1%), and co-habiting was more common 
among those with a break in MMT (34.5% versus 17.6%). 
The median age of those with a break was 33 years, slightly 
younger than those with no break (36 years).
Clinical factors were also similar in both groups (Table 
1), although just over half (52.3%) of those with a break 
in MMT were taking a methadone dose of 60mls or less 
compared with only 32.4% of those with no break.
Of those who ever had a break in MMT, most only reported 
one break (83.9%, 73). The length of break varied from less 
than one month to 18 months but the median duration was 
two months. Females were more likely to have had shorter 
breaks compared to males but no other factors were found 
to be significant in relation to duration of MMT.
Statistical analysis showed that age was the only demographic 
factor significantly associated with not having a break: older 
clients were less likely to have a break in MMT. Three clinical 
factors were significantly associated with not having a break: 
current methadone dose higher than 60 mls, longer time 
in treatment, and less than one year in current treatment 
episode. In addition, although the numbers were small, nine 
out of the ten clients with a prescription for anti-psychotic 
medicine did not report a break in treatment.
Table 1: Demographic and clinical factors of clients with or without a break in MMT
Demographic characteristics With a break (n=87) No break (n=102)
Gender
Male 70.1% 70.6%
Age (median) 33 years 36 years
Marital status
Single 58.3% 78.4%
Co-habiting 34.5% 17.6%
Married 7.1% 3.9%
Housing
Hostel 30.4% 27.7%
Own home 26.6% 38.3%
Rented 20.3% 14.9%
Other’s home 15.2% 18.1%
Homeless 7.6% 1.1%
Employment
Unemployed 94.3% 95.1%
Employed 5.7% 4.9%
Clinical factors
Age first used opiates (median) 18 years 17 years
Length in MMT 110 months 100 months
Length of current treatment episode 24 months 36 months
Current dose of methadone
60mls or less 52.3% 32.4%
61mls or more 47.7% 67.7%
Source: Adapted from Darker et al (2015)
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The most common reasons for breaks in MMT reported by 
the study participants were: 
 ■ 21.8% – relapse to drug use
 ■  13.7% – ‘fed up with methadone’ and wanting  
to detox off
 ■ 11.4% – imprisonment or problems with the police
 ■  10.3% – difficulty with travelling to the clinic or  
clinic times
 ■ 8.0% – being ‘clean’
 ■ 6.8% – being out of the country
 ■ 6.8% – emotional events, e.g. family bereavements
 ■ 3.4% – not wanting to take methadone while pregnant
 ■ 3.4% – illness.
Reasons given for regular attendance were:
 ■ 37.5% – wanting to get or stay ‘clean’
 ■ 16.1% – wanting to avoid sickness
 ■ 13.9% – methadone dependence
 ■ 10.2% – level of services provided by clinic
 ■ 5.1% – withdrawal symptoms
 ■ 5.1% – support from family members
 ■ 4.4% – only having to attend a few times a week.
The findings of this study in relation to older age and 
higher methadone dose being predictors of retention in 
MMT correspond with the findings of other national and 
international research studies. The authors state that the 
finding in relation to anti-psychotics was unexpected, 
although the numbers involved were very small. They refer 
to published literature suggesting that Olanzapine, an 
antipsychotic drug, has been found to increase retention 
among clients with schizophrenia and that very occasionally 
methadone has been used to treat psychotic symptoms. The 
most common reason for break in treatment reported in 
other studies has also been relapse to drug use.
While the study confirms that higher methadone doses may 
improve retention in treatment, the authors recommend 
that this should be balanced against the known side-effects 
of increasing the dosage, e.g. constipation, hypotension, 
drowsiness and increased dependence. The second 
recommendation is in relation to prescribing anti-psychotics 
to clients with psychotic disorders in order to improve 
retention. The authors also recommend that further research 
be carried out to explore the impact of schizophrenia on 
MMT and that more in-depth research be carried out on the 
reasons for breaks in treatment in those groups known to be 
at higher risk.
(Suzi Lyons)
1.   Darker C, Ho J, Kelly G, Whiston, L and Barry J (2015) 
Demographic and clinical factors predicting retention in 
methadone maintenance: results from an Irish cohort. 
Irish Journal of Medical Science, Early online. http://www.
drugsandalcohol.ie/24022/
Low-threshold residential stabilisation 
service (LTRSS) in Ireland 
In June 2014 the Ana Liffey Drugs Project (ALDP) published 
a position paper proposing the provision, on a three-
year demonstration basis, of a low-threshold residential 
stabilisation service (LTRSS). The paper outlines the concept 
of LTRSS and how this differs from current services as well 
as describing how the service would operate and the steps 
required to begin implementation.1 
Definition of LTRSS
The overall aim of an LTRSS is to provide a ‘genuine person-
centred service, catering for those with greatest need’. The 
paper describes LTRSS as follows:
 ■  low threshold – barriers to entry are kept as low as 
possible; 
 ■  residential – medically-led inpatient programme,  
with psychosocial support and follow-up care; 
 ■  stabilisation – stabilising the individual’s drug use, as  
well as providing detoxification (if appropriate) and 
referral to community or residential services; 
 ■  access to the service based on individual need, as 
measured by a comprehensive assessment tool; and 
 ■  time-bound (no more than a 28-day stay), but flexible  
to meet the client’s needs.
The proposed new service is described as differing from 
services currently available in Ireland in that it is open access, 
based on a holistic assessment of need and not determined 
by the individual’s drug use. There would be no cost to the 
client. Outcomes would not be solely clinically based but 
would also focus on enhanced stability. 
Rationale
A number of local and national policy documents which 
support the development of LTRSS in Ireland are cited in 
the position paper. In particular, the feedback from the 
consultation process for the current National Drugs Strategy 
(2009–2016) and the strategy itself highlighted the need 
for services tailored to the needs of individuals and also the 
need to enhance all aspects of treatment, stabilisation and 
harm-reduction services. 
While there is a general recognition of a need for expanded 
residential treatment options, the paper argues that services 
for polydrug users require particular attention. Polydrug 
use is a significant factor in drug-related deaths and as 
Ireland has one of the highest rates of drug-related deaths in 
Europe, there is a very strong rationale for the development 
of residential services which are not restricted to single drug 
use and which are responsive to the chaotic lifestyles of 
polydrug users. 
Methadone maintenance treatment (continued)
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The paper states that polydrug users’ access to the majority 
of existing residential stabilisation and detoxification 
services is restricted, and that an LTRSS would provide a 
more flexible treatment model adapted to the needs of this 
particular at-risk group.
At the same time, the paper recognises that the client’s 
presenting needs, as opposed to the potential clinical 
outcome, should be the primary determinant of service 
provision. The paper lists patient characteristics that can help 
determine whether a client is likely to benefit from in-patient 
provision. These include:
 ■ dependence on more than one drug,
 ■ physical complications,
 ■ co-morbidity,
 ■ history of complications during previous withdrawals,
 ■ chaotic polydrug use,
 ■ pregnancy,
 ■ failed outpatient withdrawal, and
 ■  inability to cope with out-patient withdrawal owing to 
isolation, homelessness or lack of support.
The proposed LTRSS would target those presenting  
with these characteristics through a comprehensive 
assessment process.
Principles
The LTRSS would provide a 24-hour, seven-days-a-week 
programme based on the following principles:
 ■  Access based on the person’s need at the time of 
presentation: when a bed becomes available, the person 
with the greatest need would be offered a place; there 
would be no waiting list. (See next section for a fuller 
explanation of this principle.)
 ■  Limited length of stay: maximum stay of approximately 28 
days depending on need; the goal would be stabilisation 
with an option for detoxification.
 ■  Type or level of drug use not a barrier to entry: Polydrug 
users and those with comorbid mental health issues will 
not be excluded except where the individual’s mental 
or physical health is a barrier to their receiving the 
stabilisation service.
Proposed service
Clients would be able to self-refer. An initial detailed 
assessment would be conducted following which a case 
would be brought to a team meeting to determine whether 
a client requires admission and the level of priority they 
should be given. If no bed is available, the client would be 
asked to come back on a daily basis until a bed is available. 
Prior to admission, a structured care plan would be 
developed with the client, setting out clear goals for 
the treatment episode. All clients would be seen by the 
service’s GP prior to admission, to ensure that clinical risk is 
appropriately assessed, medical history is complete and any 
necessary adjustments have been made to the care plan.
During their stay clients would be regularly monitored to 
ensure they are medically stable. The service would be 
overseen by a GP. Discharge would usually be to a residential 
treatment facility. However, discharge to day programmes, 
family or other structured supports would also be possible.
Next steps
The ALDP is currently seeking funding and a premises to 
operate the service on a demonstration basis for three years 
beginning in 2017.
(Margaret Curtin)
1.  Ana Liffey Drug Project (2015) Ana Liffey Drug Project position 
paper on the provision of low threshold residential stabilisation 
service (LTRSS )in Ireland. Dublin: Ana Liffey Drug Project. 
http://www.drugsandalcohol.ie/24100/ 
Needle exchange provision in Ireland  
in 2012
The Health Service Executive (HSE) recently published a 
review of needle exchange provision in Ireland.1 The review 
was designed to assess the effectiveness of HSE-funded 
needle exchange services, using evidence from 2012. In 
particular, the study examined:
 ■ needle exchange activity nationally, 
 ■ referral rates to health and social care, 
 ■ data collection procedures and clinical governance, and 
 ■ quality assurance and clinical governance.
Data for 2012 were collected between February and June 
2013, using a questionnaire consisting of closed and open-
ended questions. The data collection template was reviewed 
to ensure that it met the data-recording requirements 
of the European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA). All six non-statutory needle exchange 
services and all HSE regional offices returned questionnaires. 
However, of the 63 pharmacies where needle exchange 
services were available, only 33 had reported transactions in 
2012 and of these only 16 returned questionnaires.
Models of needle exchange in Ireland
The three models of needle exchange in use in Ireland in 
2012 are documented in the review. These were:
1. static – 24 sites mainly in Dublin City,
2.  outreach – 14 sites mainly in counties Dublin, Kildare, 
Laois, Offaly, Waterford and Wicklow, and 
3.  pharmacy – 63 sites in regions outside Dublin, Kildare 
and Wicklow. 
Low-threshold residential stabilisation service (continued)
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Figure 1: Number of transactions at needle exchange services, by region and model of service, 2012
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Access
Pharmacy needle exchange programmes provided the 
greatest level of accessibility, with pharmacies typically 
open six days a week and providing, on average, 48 hours 
of service weekly. On the other hand, 15 of the 24 static 
services opened for less than eight hours a week, and 
seven opened for 25–43 hours per week. Half (seven) 
of the outreach services opened for less than 25 hours a 
week, while five opened for 25–43 hours per week and two 
whenever needed.
Activity
The review indicates that 13,763 individuals used the needle 
exchange service during 2012, of which 7,359 (80%) were 
men and 1,862 (20%) were women. However, as there is no 
unique health identifier in Ireland, the authors urge caution 
in the use of these totals because individual service users 
may have been counted more than once. 
A total of 65,099 needle exchange transactions are reported 
to have occurred during 2012, with the majority (84%) 
being provided through static or outreach services in either 
Dublin North-East or Dublin Mid-Leinster (see Figure 1). The 
differences in the level of use of each exchange type is a 
reflection of the number of services available in each area.
Paraphernalia distributed
Detailed information on the quantity of injecting equipment 
distributed at all sites was made available to the reviewers, 
with the exception of two static sites where only partial 
information was available. Individual items were distributed at 
the static and outreach services, whereas packs of equipment 
were distributed at the pharmacy-based exchanges. 
Static and outreach services
In total, 156,575 syringes and 135,696 needles were 
distributed. Almost half of all syringes (49%) were fixed 
needle with a unit capacity of 1ml. In addition, the following 
items were distributed:
Vials of 10ml water for injection 75,819
Vials of 5ml water for injection 8,377
Vials of 2ml water for injection 1,572
Spoons/filters 25,450
Citric acid 20,125
Sterile swabs 20,603
Foil (for smoking heroin) 12,031
Tourniquets 476
The review points to a discrepancy between the number 
of needles and quantity of other injecting equipment 
distributed. In particular, the fact that 67,928 more needles 
than vials of water were made available is highlighted. This, 
the authors state, may signal that some equipment was 
being used more than once, contrary to best practice.
Pharmacy-based needle exchanges
A total of 11,790 packs, each containing the equipment 
for 10 sterile injections, were distributed through 
pharmacy-based needle exchanges. Each pack contained 
10 filter syringes (including needles), 10 stericups, 10 
swabs, 10 citric acid packs, 10 vials with 5ml water for 
injection and one information leaflet (harm reduction and 
safer injecting advice).
Returns policy
All services reported that they encouraged the return of used 
equipment but that this was not a condition for accessing 
new equipment. All pharmacy-based needle exchanges kept 
a record of equipment returned, but across the static and 
outreach services the level of record-keeping varied.
Needle exchange provision (continued)
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Releasing prisoners early  
– Community Return
The Community Return programme represents an attempt to 
address a trend of rising prison numbers and increasing prison 
costs identified in the report of the Thornton Hall Project 
Review Group in 2011.1 Concerns about prison overcrowding 
and projected further growth in prison numbers led the Group 
to recommend alternatives to custody from two perspectives – 
front-door and back-door strategies. 
Community Return is a back-door strategy, along the lines 
of a proposal made by the Group: ‘A positive step would be 
for the Minister to introduce a form of earned temporary 
release with a requirement of community service to prepare 
offenders for release on completion of their sentences’ 
(p.60). The programme is a joint Probation Service and Irish 
Prison Service (IPS) initiative whereby selected prisoners 
Referrals and other services
The number of referrals reported to the review team 
are outlined in Figure 2. The authors state that this is an 
under-estimation of the level of referral from the static and 
outreach services. The review states that all services reported 
providing information on blood-borne viruses(BBVs) but 
that recording of the numbers referred for BBV testing or 
for hepatitis B vaccination was inconsistent in the static 
and outreach services. Referrals from the pharmacy-based 
services were recorded and reported systematically.
All services reported providing face-to-face advice on overdose 
and harm reduction as well as referrals to other treatment and 
counselling services. Other services included referral to general 
practitioners, A&E, outreach and social care services as well as 
wound care and injection site inspection. 
Quality assurance and governance
The review details the quality assurance mechanisms in 
place in the various needle exchange services. Governance 
requirements for pharmacies are set out in the Pharmacy Act 
2007, which gives the Pharmaceutical Society of Ireland powers 
of inspection, investigation and enforcement. All static and 
outreach needle exchange services work within the National 
Drug Rehabilitation Implementation Committee (NDRIC) 
framework, which is designed to ensure service providers 
offer individuals affected by drug misuse a range of integrated 
options tailored to meet their needs and create for each person 
an individual rehabilitation pathway. These services are reported 
as using a range of clinical governance approaches.
Recommendations
The review recommends a standardised electronic reporting 
mechanism for regular monitoring and reporting of all 
needle exchange transactions. It also points to the need for 
a unique identifier for each service user to remove the risk 
of individuals being reported more than once in a reporting 
year. The need for specific data on injecting of image- and 
performance-enhancing drugs is also highlighted.
An examination of the potential barriers to BBV testing and 
vaccination is also recommended in order to improve uptake 
of this opportunity for testing and vaccination.
A number of recommendations are included with regard to 
the standards that need to be in place in order to enhance 
quality assurance and clinical governance.
Finally, the review recommends the provision of injecting 
equipment (e.g. stericups, filters and foil) in addition 
to needles and syringes, and points to the possibility of 
central purchasing of stock for all non-pharmacy needle 
exchange programme as a means of strengthening value  
for money.
(Margaret Curtin) 
1.  Bingham T, Harnedy N, O’Driscoll D and Doyle J (2015) 
Review of needle exchange provision in Ireland. Dublin: Health 
Service Executive. http://www.drugsandalcohol.ie/23916/
Figure 2: Number of referrals to different services, recorded by model of needle exchange, 2012
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are granted temporary release on condition they perform 
unpaid supervised work in the community. 
A recent evaluation of the programme describes the 
Community Return programme as ‘a unique and innovative 
initiative, developed and introduced in Ireland in 2011’.2 
It began as a pilot between October 2011 and April 
2012, and proved to be ‘extremely successful in assessed 
compliance with the conditions of the release and 
behaviour’ (p.13), and in terms of the very low level of 
reconviction of participants. The success of the pilot led to 
the programme being mainstreamed.
 
The evaluation was conducted to assess the ‘operation, 
impact, and effectiveness of the Community Return 
programme through a piece of descriptive and evaluative 
research’ (p.8). The study cohort comprised all 761 
Community Return programme participants between 
October 2011 and 31 December 2013. A mixed methods 
approach was used in the study, as well as analysis of 
anonymised pre-existing data on participants held by the 
IPS. Questionnaires were completed by relevant IPS and 
Probation Service personnel. 
The Community Return programme participants were 
predominantly male, with women comprising approximately 
6%. Seventy-seven per cent of participants were aged 
between 21 and 40, with the greatest concentration of both 
genders (43%) being aged between 21 and 30 years.
Some of the key findings are listed below:
 ■  62% of participants were from Leinster, and 43% of all 
participants were from Dublin. Of the total population 
who commenced the programme, approximately 53% 
were located in three major urban areas (Dublin, Cork 
and Limerick).
 ■  Of the 761 offenders who commenced the programme, 
90% were serving custodial sentences of less than six 
years, and 45% were serving sentences of between two 
and four years imprisonment. The average sentence 
length was 3.2 years.
 ■  40% of participants had been convicted of drug 
offences, 16% of assaults and related offending, and 9% 
of robbery and related offences. 
 ■  38% of participants were released from open prisons 
– Shelton Abbey and Loughan House. Among closed 
prisons, Mountjoy Prison contributed the highest 
proportion of participants, at 11%.
 ■  Of the 761 participants who had commenced the 
programme, 548 had completed it and 108 were still in 
progress. Eighty-eight, approximately 11%, breached 
conditions of the programme and were returned to 
custody. Of those participants released during the first 
year of the programme (n=233), 91% had not been 
committed to prison on a new custodial sentence in the 
period up to the end of 2013.
 ■  9,580 weeks of unpaid work, comprising 201,056 
hours, were completed by participants. Based on the 
national minimum wage in 2014 for an adult worker 
of €8.65 per hour, this represents €1,739,135 worth 
of unpaid work completed for the community by 
Community Return participants.
The most common types of work undertaken by participants 
were landscaping/gardening, painting/decorating and 
renovation, with the study finding ‘participants preferring 
work which allowed them to see a job through from 
beginning to end rather than constant switching between 
jobs’ (p.9). Supervisors interviewed for the study reported 
that participants performed positively in their work and 
displayed a positive attitude towards the work.
 
Over 80% of Probation Officers attributed participant 
compliance primarily to a desire to avoid returning 
to prison. In some cases this was complemented by 
secondary motivational factors such as ‘participant 
enjoyment of the work experience, appreciation of their 
early release or, a sense of commitment to the Community 
Return contract’ (p. 9).
 
The single biggest difficulty faced by participants following 
their release involved access to social protection entitlements 
(‘social welfare’), affecting one third of participants. Other 
reported challenges included coping with the strictness and 
frequency of the signing-on conditions, difficulties accessing 
entitlements and payments, and time and costs in travelling 
to worksites. Particular benefits of the programme included 
the ‘structure and routine which aided re-integration, the 
work ethic and self-esteem developed, their positive profile 
in working in the community and the learning of work skills 
transferable to employment’ (p.9). The programme also 
reportedly helped participants ‘stay out of trouble…, by 
keeping them occupied, providing positive supports and 
a starting point to build on, particularly in the early stages 
after release’ (p.10); research shows that newly-released 
prisoners are particularly vulnerable to relapse to anti-social 
behaviour and offending.
 
The report concludes that the Community Return 
programme has potential for further expansion. There 
is, the report concludes: ‘capacity available at present on 
supervised Community Service sites that could be used to 
accommodate extra prisoners on the Community Return 
Programme. It is recommended that the Community Return 
Programme selection process be reviewed and revised as 
appropriate to, as outlined, expand the Community Return 
Programme, enhance supervised resettlement and reduce 
the prison population’ (p.43).
In their joint strategic plan for 2015–2017, the IPS and the 
Probation Service have committed to implementing many 
of the recommendations in the evaluation report including 
aiming to match or exceed the target of 450 participants 
each year in reparative and restorative structured releases. 
(J Connolly)
1.  Thornton Hall Project Review Group (2011) Report of the 
Thornton Hall Project Review Group Dublin: Department of 
Justice and Equality http://www.drugsandalcohol.ie/15678/
2.  Irish Prison Service & Probation Service (2014) Community 
return: a unique opportunity. A descriptive evaluation of the 
first twenty six months (2011–2013). Dublin: Department of 
Justice and Equality. http://www.drugsandalcohol.ie/23016/
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Inchicore Bluebell Community Addiction 
Team – annual review 2014
The Inchicore Bluebell Community Addiction Team (IBCAT) 
recently published its 2014 annual review.1 IBCAT was formed 
in 2011 with the merger of Inchicore Community Drugs 
Team and Bluebell Addiction Service. The service underwent 
a change of leadership in 2014, with Stuart Fraser succeeding 
Celine Martin, who was director for 15 years. 
Services
IBCAT recognises that many of its users struggle with issues 
such as homelessness, poverty and mental health problems, 
and aims to offer a holistic approach to addiction treatment. 
In 2014 the service provided 25,311 interventions to 
problem drug users, their children and families. This was a 
slight increase on 2013, achieved despite funding cutbacks. 
Services provided include:
 ■ key working, 
 ■ counselling,
 ■ a drop-in service,
 ■ a children’s project, 
 ■ family support, 
 ■ outreach (including prison visits), and 
 ■ aftercare.
IBCAT operates several groups for specific target 
populations. The women’s and men’s groups offer a safe 
environment for discussion and support around gender-
specific issues. The family support group offers a safe space 
and peer supports for local people living with addiction. 
The cannabis group offers a peer support model to help 
service users make more informed choices and to reduce 
their usage. Progression of clients in the cannabis group 
is tracked every three months by evaluating how cannabis 
use is affecting the client financially, physically, emotionally 
and socially. 
Let It Shine programme
The main focus of IBCAT’s 2014 annual review is the pilot 
polysubstance misuse group. The ‘Let It Shine’ group was 
created in response to a perceived trend of service users 
misusing more than one drug. This trend had also been 
reported in a 2010 ethnographic study of drug use in the 
Canal Communities area.2
Ten IBCAT clients took part in the pilot – five women and five 
men, all of whom were also on the methadone programme. 
The average age of the participants was 38, and the average 
number of different drugs being used weekly before 
attending the group was five. The programme lasted 12 
weeks and the aim was ‘to give those attending factual, 
relevant information so that they could be more aware of 
their drug use and make more informed choices…Peer 
support is to be encouraged at all times’ (p. 19).
A contingency management method of treatment was 
used, whereby each participant was given a loyalty card and 
received incentives for regular attendance. The facilitators 
monitored the behaviours they were trying to change, 
including attendance and abiding by group rules. Positive 
reinforcement was in the form of credits, which could be 
exchanged for phone credit, food vouchers and so on. 
When the participant did not attend or the group rules were 
broken, positive reinforcement was withheld. The three 
aims of a contingency management approach are to reduce 
alcohol and drug use, retain problem drug users in treatment 
programmes, and promote positive contributions to society. 
The programme was evaluated using two metrics: (1) drug 
spend before and after the programme, and (2) a ‘happiness 
scale’ to test for changes in happiness, again before and 
after the programme. Table 1 tracks the changes in drug use 
and drug-related spending over the course of the 12-week 
programme. Although the number of participants is very 
small (n=10), the reductions in drug use are notable. 
Table 1: Comparison of use of, and money spent on, drugs before and after participation in pilot polysubstance misuse 
group, 2014
Drug Number of participants using weekly 
(total participants=10)
Average weekly spend
Before After % Change Before After % Change
Heroin 8 3 -63% €115 €32 -74%
Cannabis 5 4 -20% €97 €45 -54%
Alcohol 5 3 -40% €102 €52 -49%
Crack cocaine 4 2 -50% €225 €25 -89%
Benzodiazepines 4 3 -25% €27 €15 -45%
Source: Inchicore Bluebell Community Addiction Team (2015): Appendix II 
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Of particular interest are the 74% decrease in average 
weekly spend on heroin, and the 89% decrease in the 
average weekly spend on crack cocaine. The number 
of clients using heroin reduced from eight before the 
programme to three after the programme. 
Increases in happiness were reported across the nine areas 
of their lives about which participants were asked, ranging 
from a 13% increase in happiness about their ‘personal life’ 
and a 14% increase in happiness in relation to their ‘drug 
use’ up to a 37% increase in ‘job or educational prospects’ 
and a 38% increase in relation to their ‘social life’. Overall, 
participants reported a 39% increase in ‘general happiness’. 
The happiness scores for individual participants were  
not reported. 
(Martin Grehan)
1.  Inchicore Bluebell Community Addiction Team (2015) 
Inchicore Bluebell Community annual review 2014. Dublin: 
Inchicore Bluebell Community Addiction Team. http://
www.drugsandalcohol.ie/24226/ For further information on 
IBCAT, visit www.icdt.eu
2.  Saris A J and O’Reilly F (2010) A dizzying array of substances: 
an ethnographic study of drug use in the Canal Communities 
area. Dublin: Local Drugs Task Force. http://www.
drugsandalcohol.ie/13503/ 
Coolmine Therapeutic Community 
annual report 2014
The Coolmine Therapeutic Community (CTC) annual 
report for 2014 was launched by Aodhán Ó Ríordáin TD, 
Minister of State with special responsibility for the Drugs 
Strategy, on 14 July 2015.1 It contains information and 
statistics relating to services, strategic partners, funders 
and supporters.
The year 2014 saw CTC providing treatment and 
rehabilitation services to over 1,250 people, supporting 
them and their families in overcoming their addiction.  
The report notes the continuing increased demand for 
CTC’s services. The services offered by CTC and the 
numbers of people accessing them in 2014 are shown  
in Table 1 overleaf.
New initiatives during 2014 were established and 
resourced through existing funding. February 2014 
saw the establishment of the ‘Parenting under Pressure 
Programme’, which has been used by clients from across 
the service. Most notably, during May 2014 CTC began 
to implement its pilot ‘Community Alcohol Treatment 
Programme’ (CATP). Also started in 2014 was a ‘Recovery 
through Nature’ (RtN) programme, which provides 
clients with the opportunity to volunteer in a nature-
rich environment once a week, and offers an additional 
therapeutic outlet for clients to aid their retention in 
service while gaining new life skills. During the first six 
months of this programme, 84 clients participated and 
the retention rate was 73%. CTC clients volunteered over 
3,000 hours in conservation projects in Fingal County 
Council Millennium Park, Tolka Area Partnership, Wicklow 
Mountains National Park, and in Dublin City Council 
projects such as Bull Island biosphere conservation works 
and bulb/flower planting in St Anne’s Park.
Coolmine’s work is evidence-based and its commitment 
to formal research is evidenced by the completion of its 
three-year longitudinal study, due to be published in 2015. 
Among the key findings of the study are:
 ■  71% of clients were drug-free 24 months after 
concluding therapy,
 ■  97% of clients did not engage in criminal activity 24 
months after therapy, and
 ■ 25% of clients were employed 24 months after   
 therapy.
Coolmine hosted the European Working Group on Drugs-
Oriented Research (EWODOR) symposium at Trinity 
College Dublin in May 2014 and will host the conference 
of the European Federation of Therapeutic Communities 
(EFTC) in 2017.
 
(Vivion McGuire)
1.  Coolmine Therapeutic Community (2015) Annual 
review 2014 Dublin: CTC. Available at http://www.
drugsandalcohol.ie/24309/ 
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Table 1: Services/interventions offered by CTC, number of participants and outcomes, 2014 
Service Type of intervention No of participants Outcomes
Ashleigh House • Therapeutic groups 
• Health promotion
• Relapse prevention
• Social skills 
• Self/peer evaluation groups 
• Art classes
• Computer courses
• Horticultural projects
• Complementary therapies 
67 women •  23 clients had a methadone 
detox and 18 completed  
their detox.
• 51 mothers were worked with: 
–  22 mothers had their child 
(children) on site on a 
permanent basis
 –  28 children were worked  
with and attended the  
full-time crèche
Coolmine 
Lodge
• Therapeutic groups 
• Health promotion
• Relapse prevention
• Social skills 
• Self/peer evaluation groups 
• Art classes
• Computer courses
• Horticulture
• Complementary therapies 
147 men •  11 clients had a methadone 
detox and 73% completed  
their detox.
•  42% of admissions were referrals 
from prison/probation services.
Outreach • Prisons and Community 981 clients •  710 clients assessed by outreach 
services teams:
–  131 client assessments for 
methadone detox admission
 –  353 client placements  
in Ana Liffey/CTC  
pre-entry groups
 –  65 expectant mother and child 
assessments for admission 
Drug-free day 
programme
54 clients  
(Lord Edward Street)
19 clients (Dublin 15)
• 38 new admissions
• 14 progressions to aftercare
• 9 graduated
• 4 progressions to aftercare
Welcome 
Stabilisation 
Programme
 54 clients • 49 new admissions
•  17 progressions to  
further supports
Family support 
services
• Group and 1:2:1 setting •  56 attended weekly  
support groups
• 46 were supported 1:2:1 
• 19 attended Community     
    Reinforcement Approach Family  
    Training (CRAFT) groups 
Career 
Guidance 
Service
• Career guidance sessions
•  Community Employment (CE) 
Schemes
• Literacy support
•  Business in the Community (BiTC) 
programme
• Work placements 
• Volunteer work
427 individual 1:2:1 
sessions with Career 
Guidance officer
•  238 clients seen in group career 
guidance sessions
•  146 clients applied for  
education/training
• 14 CE Schemes 
•  47 clients provided with  
literacy support
•  29 clients took part in BiTC 
programme
•  39 clients gained placements  
or volunteer work
Contingency 
Management 
Programme
31 clients • 24 new admissions 
•  20 progressions to  
further supports
Coolmine annual report (continued)
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EMCDDA update
Drugs policy and the city in Europe
On 25 June 2015, ahead of International Day Against 
Drug Abuse And Illicit Trafficking (26 June), the European 
Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 
published Drugs policy and the city in Europe.1 The paper 
looks at drugs in cities across Europe, revealing how some 
cities are developing drug strategies of their own.
The European Union is one of the most urbanised areas 
in the world and its cities are set to become more densely 
populated. Currently 73% of the EU’s population resides in 
cities and this is projected to increase to 82% (or 30 million 
new residents) by 2050. The report identifies 10 European 
capitals with a dedicated drugs strategy: Berlin, Bucharest, 
Copenhagen, Helsinki, Lisbon, Madrid, Prague, Stockholm, 
Vienna and Warsaw. The report focuses on four topics: urban 
spaces and drug use; businesses and recreational drug use; 
city-level drug policies; and coordinating and funding city-
level policies.
Urban spaces and drug use
Eight capital cities report current ‘open drug scenes’, which 
can vary from the ‘concentrated’ (up to hundreds of users 
per day) to the ‘dispersed’ (multiple smaller gatherings). 
Despite these variations, common features exist, namely: the 
presence of polydrug use, health issues linked to injecting, 
and problems relating to congregations of users. The report 
explores some of the responses currently used, including 
needle- and syringe-exchange programmes, drop-in centres, 
drug consumption rooms, and measures to reduce drug-
related litter (e.g. sharp bins, needle-exchange machines).
Businesses and recreational drug use
Cities contain a high density of premises where psychoactive 
substances are sold and consumed. Frequently, specific areas 
exist where many of these businesses are clustered together. 
This can give rise to zones where drug use and intoxication 
are tolerated, if not accepted. Given the diversity of the drug 
problems found in such areas, a spectrum of responses is 
being implemented. These range from prevention and harm-
reduction initiatives in recreational settings (e.g. information 
campaigns, pill-testing) to legislative measures targeting new 
psychoactive substances and street-based outlets for their sale.
City-level drug policies
The report defines city-level policies as ‘measures taken by 
local policy actors to address all or some aspects of drug 
problems in a specific urban location’. It finds that city-level 
drug strategies frequently mirror the focus of national and 
regional level documents. Other cities, however, adopt a 
more thematic approach, addressing specific issues such as 
open drug scenes (Copenhagen, Oslo), anti-social behaviour 
(Dublin) and crack cocaine (London and Paris). 
Coordinating and funding city-level policies
Generally, city authorities are formally responsible for the 
coordination of city-level drug policy, in some cases this 
being established by law (Helsinki, Madrid, Warsaw). Some 
cities have dedicated drug policy units, while others address 
drug issues via generic policy units. Officially appointed 
‘city drug coordinators’ exist in some capitals. Where no 
formal coordination structures exist at city level, national-, 
regional- or local-level structures are responsible for strategy 
implementation (Ankara, Bratislava, Bucharest, and Dublin). 
Irish parliamentarians visit EMCDDA
A delegation of members of the Joint Committee on Justice, 
Defence and Equality of the Oireachtas visited the EMCDDA 
on 4 and 5 June 2015. The delegation attended the launch 
of the European Drug Report 2015 (see separate report on 
this publication elsewhere in this issue), after which they met 
EMCDDA experts regarding the Portuguese drug law in the 
context of drug legislation in the EU member states. They 
also met the EMCDDA Director.
Following the visit to the EMCDDA, the delegation held 
meetings with Dr João Goulão, a representative of the 
Commission for Addiction Dissuasion (CDT) in Portugal, 
members of the Committee on Health of the Portuguese 
Parliament, and the National Deputy Director of the 
Polícia Judiciária from Portugal. They also visited the Taipas 
treatment centre in Lisbon.
1.  European Monitoring Centre for Drugs and Drug Addiction 
(2015) Drugs policy and the city in Europe. EMCDDA Papers. 
Luxembourg: Office for Official Publications of the European 
Communities. http://www.drugsandalcohol.ie/24173/ 
Recent publications
Flexible emotion-based decision-making behavior varies 
in current and former smokers
Briggs Z, O’Connor M, Jollans EK, O’Hallorhan L, Dymond S, 
Whelan R (2015) Addictive Behaviors (45): 269–275 
www.drugsandalcohol.ie/24350/
The influence of smoking status on flexible decision-making 
was examined. Both current and former smokers displayed 
poorer decision-making than non-smokers. Current smokers 
had poorer flexible decision-making than former and  
non-smokers.
Young people’s perceptions of tobacco packaging: a 
comparison of EU Tobacco Products Directive & Ireland’s 
Standardisation of Tobacco Act
Babineau K, Clancy L (2015) BMJ Open (5/6) e007352 
URL: http://bmjopen.bmj.com/content/5/6/e007352.
abstrac...
www.drugsandalcohol.ie/24349/
The removal of brand identifiers, including colour, font 
and embossing, reduced the perceived appeal of cigarette 
packs for young people across all three tested brands. Packs 
standardised according to Irish legislation were perceived 
as less attractive, less healthy and smoked by less popular 
people than packs which conform to the EU TPD (Tobacco 
Products Directive) 2014 guidelines.
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Patients accessing ambulatory care for HIV-infection: 
epidemiology and prevalence assessment 
Tuite H, Horgan M, Mallom PWG, McConkey SJ, Mooka 
B, Mulcahy F, Walsh C, O’Hora A, O’Flanagan D, Bergin C, 
Fleming C (2015) Irish Medical Journal (108/7) 
URL: http://www.imj.ie//ViewArticleDetails.aspx?Article...
www.drugsandalcohol.ie/24348/
This study describes the demographics and treatment  
status of HIV-infected adults accessing ambulatory care 
in the Republic of Ireland and estimates diagnosed HIV 
prevalence rates.
Youth engagement with an emerging Irish mental health 
early intervention programme (Jigsaw): participant 
characteristics and implications for service delivery 
O’Reilly A, Illback R, Peiper N, O’Keeffe L, Clayton R (2015) 
Journal of Mental Health Early online: pp. 1–6
www.drugsandalcohol.ie/24343
Data about young people who engaged with Jigsaw for the 
first time during 2013 were captured through an online 
system designed to record salient clinical, case management, 
service delivery, and outcome information. Participant 
characteristics were summarised to portray the young 
people who engaged with the service (N=2,420).
The majority of young people engaging with Jigsaw were 
female, aged 15–17 years, and were referred by their 
parents. Over half were in full-time education, although 
many 21–25-year-olds were unemployed. Young people 
presented with a range of difficulties, which varied by age 
and gender. They reported high levels of distress, with age 
and gender having a significant impact on their well-being.
Implementing a harm reduction approach to substance 
use in an intimate partner violence agency: practice 
issues in an Irish setting
Morton S, Hohman M, Middleton A (2015) Partner Abuse 
(6/3): 337–350
www.drugsandalcohol.ie/24305/
There has been growing recognition of the co-occurrence 
of substance use and intimate partner violence (IPV) 
victimisation in women’s and men’s lives, yet many IPV 
service providers have not developed an integrated response 
to these issues. Fewer still have implemented substance 
use services from a harm reduction approach. This article 
outlines the approach, policy changes, initial outcomes, 
and learning points for an IPV agency in Ireland, which 
implemented a harm reduction response to female IPV 
survivors who were also using substances problematically. 
Barriers and challenges for staff and management seeking to 
coordinate and integrate service delivery on the dual issues 
are also presented.
Attitudes and perceived risk of cannabis use in Irish 
adolescents 
Barrett P, Bradley C (2015) Irish Journal of Medical Science 
Early online 
www.drugsandalcohol.ie/24297
This was a descriptive, cross-sectional study using a 
structured, anonymous questionnaire. The study was 
undertaken in nine public and private secondary schools in 
Cork City and suburbs. Students aged 15–18 and in fourth, 
fifth or sixth year of school were included.
What are reasons for the large gender differences in the 
lethality of suicidal acts? An epidemiological analysis in 
four European countries 
Mergl R, Koburger N, Heinrichs K, Székely A, Tóth MD, 
Coyne J, Quintao S, Arensman E, Coffey C, Maxwell M, 
Värnik A, van Audenhove C, McDaid D, Sarchiapone M, 
Schmidtke A, Genz A, Gusmão R, Hegerl U (2015) PLoS ONE 
(10/7) e0129062 
URL: http://journals.plos.org/plosone/article?id=10.137...
www.drugsandalcohol.ie/24288/
In Europe, men have a lower rate of attempted suicide 
compared to women and at the same time a higher rate 
of completed suicides, indicating major gender differences 
in lethality of suicidal behaviour. The aim of this study was 
to analyse the extent to which these gender differences 
in lethality can be explained by factors such as choice of 
more lethal methods or lethality differences within the same 
suicide method or age group. In addition, we explored 
gender differences in the intentionality of suicide attempts.
Men used highly lethal methods in suicidal behaviour more 
frequently, but there was also a higher method-specific 
lethality, which together explained the large gender 
differences in the lethality of suicidal acts. Gender differences 
in the lethality of suicidal acts were fairly consistent across 
all four European countries examined. Males and females 
did not differ in age at time of suicidal behaviour. Suicide 
attempts by males were rated as being more serious 
independent of the method used, with the exceptions 
of attempted hanging, suggesting gender differences in 
intentionality associated with suicidal behaviour. These 
findings contribute to understanding of the reasons for 
gender differences in the lethality of suicidal behaviour and 
should inform the development of gender specific strategies 
for suicide prevention.
The voice of the child in social work assessments:  
age-appropriate communication with children
O’Reilly L, Dolan P (2015) British Journal of Social Work  
Early online
URL: http://www.tusla.ie/uploads/content/Age_Appropriat...
www.drugsandalcohol.ie/24246
This article describes a child-centred method for engaging 
with children involved in the child protection and welfare 
system. One of the primary arguments underpinning 
this research is that social workers need to be skilled 
communicators to engage with children about deeply 
personal and painful issues. 
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There is a wide range of research that maintains play is the 
language of children and the most effective way to learn 
about children is through their play. Considering this, the 
overarching aim of this study was to investigate the role of 
play skills in supporting communication between children 
and social workers during child protection and welfare 
assessments. The data collection was designed to establish 
the thoughts and/or experiences of participants in relation 
to a Play Skills Training (PST) programme designed by the 
authors. The study revealed that the majority of social work 
participants rated the use of play skills as a key factor for 
effective social work assessments of children. Of particular 
importance, these messages address how social work 
services can ensure that the voice of children is heard and 
represented in all assessments of their well-being and future 
care options.
Increase in diagnoses of recently acquired HIV in people 
who inject drugs
Glynn R, Giese C, Ennis O, Gibbons Z, O’Donnell K, Hurley 
C, Ward M, Igoe D, Fitzgerald M (2015) EPI-Insight (16/7) 
URL: http://ndsc.newsweaver.ie/epiinsight/1bumldnml2k?a...
www.drugsandalcohol.ie/24244
An increase in recently acquired HIV in people who inject 
drugs (PWID) has been noted in Dublin since early 2015. 
We have defined recently acquired HIV infections as those 
in which the person tests positive using a combined HIV 
antigen/antibody screening assay, negative or indeterminate 
on a confirmatory immunoblot assay, and is p24 antigen 
positive, or has had a HIV negative test within the 12 months 
prior to the positive test or who suffers an acute HIV sero-
conversion illness.
A multidisciplinary incident team has been set up by the 
Director of Public Health in Dublin to investigate and 
respond to the increase. The team includes public health and 
HIV physicians, GPs providing services for drug users and 
homeless populations, Health Service Executive (HSE) social 
inclusion staff, addiction clinicians, a clinical virologist and 
the Health Protection Surveillance Centre (HPSC) Ireland. An 
epidemiological investigation is under way. Clinicians from 
the drug services are concerned that the increase is linked to 
injection of a synthetic cathinone PVP (with the street name 
Snow Blow), with consequent more frequent injecting and 
unsafe sexual and needle-sharing practices. This has mainly 
been seen in chaotic drug users, who report polydrug use, 
and are often homeless.
Evidence to date indicates that the increase has been 
occurring since June 2014. Fifteen cases of recently 
acquired HIV infection (confirmed cases) and one case with 
epidemiological link to a recently acquired HIV infection 
(probable case) have been diagnosed in PWID in Dublin 
from June 2014 to June 2015. Of the 15 cases, seven are 
p24 antigen positive, indicating very recent infection. A 
further 16 possible cases among PWID are currently under 
investigation and new cases continue to be detected. 
Among the 16 confirmed and probable cases, 11 are male 
and five are female, and the mean age is 35 years (range 24 
to 51 years). A case control study is under way to identify 
any association between use of Snow Blow and an increase 
in unsafe injecting practices, at-risk sexual behaviour and 
acquisition of HIV.
Treatment outcome for adolescents abusing alcohol and 
cannabis: how many ‘reliably improve’? 
Smyth BP (2015) Irish Medical Journal (108/5): 137–139
www.drugsandalcohol.ie/23955/ 
Alcohol and cannabis are the primary substances 
contributing to referrals of adolescents to substance abuse 
treatment services. Their outcome has not been examined 
in Ireland. A three-month follow-up was conducted in an 
outpatient adolescent treatment program. We followed 
up 35 high-risk users of alcohol and 55 high-risk users 
of cannabis. Although the high-risk drinkers achieved a 
significant reduction in median number of days drinking 
(p=0.004), only four (11%) were abstinent at follow-up. 
A further five (14%) achieved a reliable reduction in days 
of drinking. The high-risk cannabis users demonstrated 
a significant drop in median days of use (p<0.001), 
although only six (11%) were abstinent at follow-up. A 
further 20 (36%) achieved a reliable reduction in days of 
use. Calculation of reliable change allows examination of 
outcomes which fall short of the elusive goal of abstinence.
Upcoming events
October 2015
5–8 October 2015
Centre for Addiction Research and Education Scotland – 
14th CARES Conference 
Venue: Caird Hall, Dundee, Scotland
Further information: www.isamdundee2015.com 
The topic for this year’s CARES conference will be ‘Novel 
interventions in the substance misuse field’. The speakers 
are coming from China, USA, Abu Dhabi, Germany, UK 
and Netherlands. They will present topical and clinically 
applicable material on new evidence showing the efficacy 
of neurosurgery, vaccines, heroin, cannabinoids and 
other novel psychoactive substances as potential future 
therapeutic agents and interventions in the treatment of 
substance misuse.
8–9 October 2015
Alcohol use conference
Venue: Portmarnock Hotel 
Further information: http://www.ndublinrdtf.ie/event/
alcohol-use-confer...
The North Dublin Regional Drugs And Alcohol Task Force 
is planning a conference addressing alcohol use in October 
2015. The event will be open to all professionals working 
with people & families in North County Dublin and North 
Fingal affected by drugs and alcohol. 
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16 October 2015
Cannabis - why not? A quality standards based 
conference for those who work with young people and 
families at risk of substance misuse 
Venue: Radisson Blu Royal Hotel, Dublin 8
Further information: http://www.eventbrite.ie/e/cannabis-
why-not-regist...
The day will include the following guest speakers:
Kevin A. Sabet PhD, consultant, advisor to three US 
presidential administrations, and assistant professor, has 
studied, researched, written about, and implemented drug 
policy for almost 20 years. He worked in the Clinton (2000) 
and Bush (2002–2003) administrations, and in 2011 stepped 
down after serving more than two years as the senior advisor 
to President Obama’s drug control director. He is the author 
of Reefer sanity: seven great myths about marijuana (New 
York: Beaufort Books, 2013).
Deirdre Boyd, based in the UK, owns DB Recovery Resources 
(http://www.dbrecoveryresources.com/), which supplies a daily 
news service to the international alcohol/drug-treatment field 
on addiction recovery. Prior to that, she was for over 20 years 
CEO of the Addiction Recovery Foundation, editor of Addiction 
Today, cofounder/organiser of the UK/European Symposia on 
Addictive Disorders, and author of Addiction & Recovery: self-
help for friends, families and addicts (2010). Deirdre will discuss 
the findings of an evaluation of the declassification of cannabis 
in the UK and also what DB Recovery Resources is and how it 
can assist those working with people in substance misuse. 
Philip James trained as a psychiatric nurse in Dublin in 
1999, was appointed as the first Clinical Nurse Specialist 
in Adolescent Substance Misuse in 2006 with YoDA, and 
is a qualified cognitive behavioural therapist. In addition 
to his clinical work, he has been involved in a number of 
research projects and publications. He lectures on addiction 
and mental health topics at a number of colleges including 
University College Dublin, Trinity College Dublin, University 
of Limerick and the Irish College of Humanities and Applied 
Sciences. Philip will present YoDA’s findings on a study 
co-authored with Dr Bobby Smyth about ‘cannabis – the 
perspectives of young smokers’.
Parentline will present information on non-violent resistance 
training – a brief, practical and research-based programme 
aimed at providing parents with strategies for coping with 
child-to-parent violence. 
November 2015
12 November 2015 
CityWide Drugs Crisis Campaign conference
Venue: The Hogan Suite, Croke Park, Dublin 3
Further information: http://www.citywide.ie/news/ 
 
2015 marks the 20th anniversary of CityWide Drugs Crisis 
Campaign. It is also a year when drug policy reform issues 
such as decriminalisation are being put on the policy agenda 
in Ireland in advance of the development of the next National 
Drugs Strategy. As part of its 20th anniversary celebrations, 
CityWide is holding a major conference on the overall theme 
of Drug Policy Reform to look at the following questions:
1.  What have we learnt from 20 years’ experience of trying 
to tackle the drugs issue here in Ireland?
2.  How can we link our experience in Ireland to the 
international debate on moving from the ‘war on drugs’ 
to a public health and human rights approach?
3.  How can we bring together the learning and evidence 
from the Irish and the international experience to feed 
into the new Irish National Drugs Strategy?
The conference will be addressed by President of Ireland, 
Michael D. Higgins. 
January/February 2016
28 January 2016
Reporting for work under the influence of drugs and 
alcohol – employers’ legal obligations
Venue: Rochestown Park Hotel, Cork
Organised by: EAP Institute
Further information: www.eapinstitute.com 
Email: anita@eapinstitute.com
25 February 2016
Reporting for work under the influence of drugs and 
alcohol – employers’ legal obligations
Venue: Hotel Kilkenny, Kilkenny
Organised by: EAP Institute
Further information: www.eapinstitute.com 
Email: anita@eapinstitute.com 
Under the Safety, Health and Welfare at Work Act 2005 all 
employees must ensure that they are not under the influence 
of an intoxicant (defined as including drugs and alcohol and 
any combination of drugs or of drugs and alcohol) to the 
extent that he or she is in such a state as to endanger his 
or her own safety, health or welfare at work or that of any 
other person. Employers are legally entitled to prevent an 
employee from working if he or she would be a danger to 
themselves or others due to being under the influence of an 
intoxicant to the extent that he or she is in such a state as to 
endanger his or her own safety, health or welfare at work, or 
that of any other person.
New measures to test all drivers, including those who 
drive company vehicles in Ireland, came into force on 27 
November 2014.  The Road Traffic Act 2014 allows Gardaí to 
conduct five random cognitive impairment tests and those 
who fail may be arrested and subject to additional medical 
examination to determine the presence of intoxicants, 
and failure will result in prosecution.  In 2015 the roadside 
impairment testing will be followed by the introduction of 
a testing device which will be used by the Gardaí conduct 
roadside drug tests.
Speakers
Maurice Quinlan, Director of the EAP Institute 
Mike Doyle, Country Manager Ireland, Alere Toxicology
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